Protocol Title: 
VRC 609: A Phase I, Open
-
Label, Dose
-
Escalation Study of the Safety 
and Pharmacokinetics of a Human Monoclonal Antibody, VRC
-
HIVMAB091
-
00
-
AB 
(N6LS), Administered Intravenously or Subcutaneously with or without recombinant 
human 
hyaluronidase PH20 (rHuPH20) to Healthy Adults
 
 
NCT:
 
03538626
 
 
Documents
:
 
·
 
IRB
-
approved 
Protocol (v
9
.0 0
7OCT2022
) 
-
 
Statistical Analysis Considerations located 
in Section 6 of the Protocol 
 
·
 
IRB
-
approved
 
Main
 
Informed Consent 
(v
9
.0
 
0
7OCT2022
) 
-
 
IRB approval date: 
31OCT2022
 
·
 
IRB
-
approved
 
Suppl
ementary
 
Informed Consent 
(v8
.0
 
07OCT2022) 
-
 
IRB approval date: 
31OCT2022
 
 
 
 
 
 
Page 
1 
of 
73
 
VACCINE
 
RESEARCH
 
CENTER
 
 
Protocol VRC 
609
 
(18
-I-
0105)
 
 
A
 
P
HASE 
I,
 
O
PEN
-L
ABEL
,
 
D
OSE
-E
SCALATION 
S
TUDY OF THE 
S
AFETY AND 
P
HARMACOKINETICS OF A 
H
UMAN 
M
ONOCLONAL 
A
NTIBODY
,
 
 
VRC
-
HIVMAB091
-
00
-
AB
 
(N6LS),
 
A
DMINISTERED 
I
NTRAVENOUSLY OR 
S
UBCUTANEOUSLY 
WITH OR WITHOUT RECOMBINANT HUMAN HYALURONIDASE 
PH
20
 
(
R
H
U
PH20)
 
TO 
H
EALTHY 
A
DULTS 
 
Study Product Provided by:
 
[CONTACT_4461] 
 
(NIAID)
,
Vaccine Research Center 
(VRC)
 
National Institutes of Health (NIH)
 
Bethesda, Maryland
 
Clinical Trial Sponsored by:
 
[CONTACT_18127], VRC
 
Bethesda, Maryland
 
IND Sponsored by:
 
[CONTACT_18127], VRC 
 
Bethesda, Maryland
 
IND 
134081 - 
held by [CONTACT_629595]:
 
[INVESTIGATOR_100364]
 
M.D.
 
VRC
 
NIAID
 
Version 
9.[ADDRESS_839592]: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
2
 
of 
73
 
 
 
TABLE OF CONTENTS
 
ABBREVIATIONS
 
................................
................................
................................
.........................
7
 
PRINCIPAL INVESTIGATOR [INVESTIGATOR_178093]
 
................................
...........
10
 
PRÉCIS
 
 
................................
................................
................................
................................
....
11
 
STATEMENT OF COMPLIANCE
 
................................
................................
...............................
13
 
1.
 
INTRODUCTION
 
................................
................................
................................
......
14
 
1.1.
 
N6LS Background
 
................................
................................
................................
......
14
 
1.2.
 
Recombinant Human Hyaluronidase PH20 (rHuPH20)
 
................................
.............
15
 
1.3.
 
Nonclinical Experience
 
................................
................................
...............................
15
 
1.3.1.
 
N6LS
 
................................
................................
................................
...........................
15
 
1.3.2.
 
rHuPH20
 
................................
................................
................................
.....................
16
 
1.4.
 
Clinical Experience
 
................................
................................
................................
.....
16
 
1.4.1.
 
N6LS
 
................................
................................
................................
...........................
16
 
1.4.2.
 
rHuPH20
 
................................
................................
................................
.....................
18
 
1.5.
 
Rationale for the Study Design
 
................................
................................
...................
18
 
1.6.
 
Research
-
specific Laboratory Assessments
 
................................
................................
19
 
1.6.1.
 
Pharmacokinetic (PK) Analysis
 
................................
................................
..................
19
 
1.6.2.
 
Anti
-
drug Antibody (ADA) Analysis
 
................................
................................
.........
19
 
1.6.3.
 
HIV Pseudovirus Neutralization
 
................................
................................
.................
20
 
1.6.4.
 
Allotype
-
specific Effects
 
................................
................................
............................
20
 
2.
 
INVESTIGATIONAL PRODUCTS
 
................................
................................
..........
21
 
2.1.
 
N6LS (VRC
-
HIVMAB091
-
00
-
AB)
 
................................
................................
...........
[ADDRESS_839593] (EDP)
 
................................
................................
............
[ADDRESS_839594]: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
[ADDRESS_839595] Discontinuation from Protocol Participation
 
..............................
32
 
4.6.
 
Criteria for Discontinuation of N6LS or N6LS+
 
rHuPH20
 
Administration
 
..............
[ADDRESS_839596]
 
................................
..............................
35
 
5.5.1.
 
Unanticipated Problem (UP) Definition
 
................................
................................
.....
[ADDRESS_839597]: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
[ADDRESS_839598] and Administration Regimen
 
................................
..............................
43
 
7.2.
 
N6LS (VRC
-
HIVMAB091
-
00
-
AB) Vialed Product
 
................................
..................
[ADDRESS_839599](s) (N6LS ± rHuPH20) for Administration
 
..................
44
 
7.5.1.
 
N6LS: Preparation for IV Administration
 
................................
................................
..
45
 
7.5.2.
 
N6LS: Preparation for SC Administration
 
................................
................................
.
45
 
7.5.3.
 
N6LS with rHuPH20: Preparation for SC 
Administration via Infusion Pump
 
..........
[ADDRESS_839600] for IV or SC Administration: N6LS and 
N6LS+rHuPH20
 
................................
................................
................................
.........
[ADDRESS_839601] PROTECTIONS AND ETHICAL OBLIGATIONS
................
48
 
8.1.
 
Informed Consent
 
................................
................................
................................
.......
48
 
8.2.
 
Risk/Benefit Assessment
 
................................
................................
............................
[ADDRESS_839602]: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
[ADDRESS_839603] Identification and Enrollment of Study Subjects
 
................................
...........
51
 
8.7.
 
Costs
 
................................
................................
................................
...........................
51
 
8.8.
 
Compensation
 
................................
................................
................................
.............
51
 
8.9.
 
Safety Monitoring
 
................................
................................
................................
.......
52
 
9.
 
ADMINISTRATIVE AND LEGAL OBLIGATIONS
 
................................
..............
53
 
9.1.
 
Protocol Amendments and Study Termination
 
................................
...........................
53
 
9.2.
 
Study Documentation and Storage
 
................................
................................
.............
53
 
9.3.
 
Clinical Monitoring, Data Collection and Data Sharing
 
................................
............
53
 
9.3.1.
 
Clinical Monitoring Plan
 
................................
................................
............................
53
 
9.3.2.
 
Data Collection
 
................................
................................
................................
...........
54
 
9.3.3.
 
Source Documents
 
................................
................................
................................
......
54
 
9.3.4.
 
Data Sharing
 
................................
................................
................................
...............
54
 
9.4.
 
Language
 
................................
................................
................................
.....................
54
 
9.5.
 
Policy Regarding Research
-
Related Injuries
 
................................
..............................
54
 
10.
 
REFERENCES
 
................................
................................
................................
...........
55
 
APPENDIX I: SCHEDU
LE OF EVALUATIONS
 
................................
................................
.......
57
 
APPENDIX II:  ASSESSMENT OF RELATIONSHIP TO STUDY PRODUCT AND 
TABLE FOR GRADING SEVERITY OF ADVERSE EVENTS
 
.............................
[ADDRESS_839604]: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
[ADDRESS_839605] OF TABLES
 
Table
 
1:
 
VRC 609 Study Schema
 
................................
................................
.............................
24
 
Table
 
2:
 
Schema for Dose
-
escalation and Repeat
-
Dosing PSRT Data Reviews
 
......................
31
 
Table
 
3:
 
Event Probabilities for Different Scenarios
 
................................
................................
39
 
Table
 
4:
 
95% Confidence Intervals of the True Rate for All Possible Number of 
Observed Events within a Dose Group
 
................................
................................
.......
[ADDRESS_839606]: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.[ADDRESS_839607]
 
DS
 
drug substance
 
ECL
 
electrochemiluminescence
 
EDP
 
ENHANZE
®
 
Drug Product
 
ELISA
 
enzyme
-
linked immunosorbent assay
 
EOI
 
end of infusion; end of injection
 
F
 
bioavailability
 
FBS
 
Fetal Bovine Serum
 
FDA
 
Food and Drug Administration
 
GCP
 
Good Clinical Practice
 
GLP
 
Good Laboratory Practice
 
HA 
 
hyaluronan
 
HCL
 
hydrochloric acid
 
HIV
 
human immunodeficiency virus
 
HLA
 
human leukocyte antigen
 
HRPP
 
Human 
Research Protections Program
 
IB
 
Investigator’s Brochure
 
ICF
 
informed consent form
 
ICH
 
International Conference on Harmonisation
 
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.[ADDRESS_839608]: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.0  
 
October 07
, 2022 
 
 
Page 
9 
of 
73
 
 
Abbreviation
 
Term
 
S[LOCATION_003]R
 
serious and 
unexpected suspected adverse reaction
 
T
½
 
half
-
life
 
TCR
 
tissue cross reactivity
 
Tmax
 
time of maximal concentration (Cmax)
 
TMB
 
3,3’,5,5’
-
Tetramethylbenzidine
 
ULN
 
upper limit of normal
 
UNAIDS
 
Joint United Nations Programme on HIV/AIDS
 
UP
 
unanticipated problem
 
USP
 
[LOCATION_002] Pharmacopeia
 
Vd
 
volume of distribution
 
VI
P
 
Vaccine Immunology 
Program
 
VRC
 
Vaccine Research Center
 
WBC
 
white blood cell
 
β
-
HCG
 
human chorionic gonadotropin
 
λz
 
terminal slope of concentration vs time 
profile
 
 
 
 
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.0  
 
October 07
, 2022 
 
 
Page 
10
 
of 
73
 
 
PRINCIPAL INVESTIGATOR [INVESTIGATOR_52548] 609: A Phase I, Open-Label, Dose-Escalation Study of the Safety and 
Pharmacokinetics of a Human Monoclonal Antibody, VRC-
HIVMAB091
-00-
AB (N6LS), 
Administered Intravenously or 
Subcutaneously with or without recombinant human 
hyaluronidase PH20 (rHuPH20)
 
to Healthy Adults 
 
 
I, the Principal Investigator [INVESTIGATOR_100365], agree to conduct the study in full 
accordance with the provisions of this protocol and all applicable protocol
-related documents.  I 
agree to conduct the study in compliance with [LOCATION_002] (US) Health and Human Services 
(HHS) regulations (45CFR 46); applicable US Food and Drug Administration (FDA) 
regulations; standards of the International C
onference on Harmonization Guidelines for Good 
Clinical Practice (E6); Institutional Review Board/Ethics Committee (IRB/EC) determinations; 
all applicable in
-country, state, and local laws and regulations; and other applicable requirements 
(e.g., US Nation
al Institutes of Health) and institutional policies. I will comply with all 
requirements regarding the obligations of investigators as outlined in the Statement of 
Investigator (Form FDA 1572), which I have also signed. 
I agree to maintain all study documentation pertaining to the conduct of this study, including but 
not limited to, case report forms, source documents, laboratory test results, and medication 
inventory records, for at least 2 years following submission of a marketing application to FDA 
(21 CFR 312.62).  If no marketing application is filed, or if the application is not approved, the 
records will be retained for two years after the investigation is discontinued and the FDA is 
notified.  The HHS protection of human subjects’ regulations require 
that institutions retain 
records of IRB/EC activities and documentation of informed consent of subjects for at least 3 
years after study completion (45 CFR 46).  No study records will be destroyed without prior 
authorization from VRC/NIAID.  Publication o
f the results of this study will be governed by [CONTACT_629596]/NIAID policies. Any presentation, abstract, or manuscript will be made available by [CONTACT_629597].
 
I have read and understand the information in th
is protocol and will ensure that all associates, 
colleagues, and employees assisting in the conduct of the study are informed about the 
obligations incurred by [CONTACT_100388].
 
 
 
Richard Wu
, MD
_______________    
NIH
-
Clinical Center Vaccine Evaluation Clinic
 
Name/Title of Principal Investigator 
      [INVESTIGATOR_52550] 
 
 
___________________________________   __________________________________ 
Signature [CONTACT_789]               
   
[INVESTIGATOR_629574]: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
11
 
of 
73
 
 
PRÉCIS
 
 
 
VRC
 
609:
 
A
 
Phase
 
I
, 
Open
-
Label,
 
Dose
-
Escalation
 
Study
 
of
 
the
 
Safety
 
and
 
Pharmacokinetics
 
of
 
a
 
Human
 
Monoclonal
 
Antibody,
 
VRC
-
HIVMAB091
-
00
-
AB
 
(N6LS),
 
Administered
 
Intravenously
 
or
 
Subcutaneously
 
with or without Recombinant 
Human Hyaluronidase
 
P
H20
 
(
rHu
PH20)
 
to
 
Healthy
 
Adults
 
Study
 
Design:  
 
This is the first
 
study in healthy adults of the N6LS monoclonal antibody (MAb). 
It is a dose
-
escalation study to examine safety, tolerability, dose, and 
pharmacokinetics
 
(PK)
 
of N6LS
 
administered intravenously (IV) and 
subcutaneously (SC) to healthy adults. For SC administration, N6LS will be 
administered alone or coadministered with 
the permeation enhancer 
rHuPH20
 
enzyme. 
Primary 
hypothes
e
s 
are
 
that N6LS administration to healthy adul
ts will 
be safe by [CONTACT_629598]
,
 
alone 
and
 
with
 
rHuPH20
 
coadministration
.  A 
secondary hypothesis is that 
all 
N6LS 
administrations 
will be detectable in human 
sera with a definable half
-
life
.
 
Product
 
Description
:
N6LS 
(VRC
-
HIVMAB091
-
00
-
AB ) 
is a h
uman 
M
Ab targeted to the HIV
-
1 CD4 
binding site. It was developed by [CONTACT_33807]/NIAID/NIH and manufactured under 
current Good Manufacturing Practice (cGMP) regulations at the VRC Vaccine 
Pi[INVESTIGATOR_629575] 
(VCMP), Leidos Biomedical Research, Inc., Frederick, MD.
 
The product is 
provided as a sterile aqueous buffered solution in 10 mL glass vials at a 
concentration of 100 mg/mL and volume of 6.[ADDRESS_839609] (EDP) 
contains 
0.5 mL of 
rHuPH20
 
formulated at a concentration of 1 mg/mL (~110,000 U/m
L
 
rHuPH20).
 
rHuPH20
 
is 
a tissue permeability modifier that depolymerizes hyaluronan (HA), increasing 
the dispersion of a substance into the subcutaneous space, wh
ich enables SC 
delivery of  co‐administered antibody (
-
ies) at higher dose volumes  (e.g., >10 mL) 
tha
t 
can
not 
be administered 
quickly 
without rHuPH20. EDP is manufactured by 
[CONTACT_350783], Inc, (San Diego, CA) for Halozyme Therapeutics, Inc. (San 
Diego
, CA) and is supplied in 
2 mL glass 
vials as a sterile, single
-
dose, injectable 
liquid
.
 
 
Subjects
:
 
Healthy
 
adults,
 
18
-
50
 
years
 
of
 
age.
 
Study
 
Plan:
 
This open
-
label study include
s
 
8 
dose 
groups to assess N6LS 
alone 
given as a 
single IV infusion at the 5, 20, or 40 mg/kg dose level (Groups 1, 3,4); a single SC 
injection at the 5 mg/kg dose level (Group 2); or in 3 administrations, 
spaced 
12 
weeks apart by [CONTACT_350761] 5 mg/kg dose level (Group
 
5), or 
by [CONTACT_629599] 20 mg/kg dose level 
(Group 6)
. 
Two additional groups will assess N6LS 
given as a single SC injection
 
mixed with 
rHuPH20 (2000 U/mL) 
at 5
 
mg/kg
 
(Group 7) or 20 mg/kg (Group 8)
 
doses
.
 
Enrollment
 
open
ed
 
with Groups 1
, 2 
and 
5; 
and was 
followed by [CONTACT_629600] 3
, 4, 
and 6
. With 
implementation of the two
 
SC
 
N6LS
+
 
rHuPH20
 
 
arms as a protocol amendment, 
Group [ADDRESS_839610]: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.0  
 
October 07
, 2022 
 
 
Page 
12
 
of 
73
 
 
 
 
VRC 609 Study Schema
 
Group
 
Subjects
 
Study 
Products
 
Dosing Schedule
 
N6LS Dose 
& Route
 
rHuPH20
 
Dose
 
Day 0
 
Week 12
 
Week 24
 
1
 
3
 
5
 
mg/kg IV
 
-
 
X
 
 
 
2
 
3
 
5
 
mg/kg SC
 
-
 
X
 
 
 
3
 
3
 
20
 
mg/kg IV
 
-
 
X
 
 
 
4
 
3
 
40
 
mg/kg IV
 
-
 
X
 
 
 
5
 
5
 
5
 
mg/kg
 
SC
 
-
 
X
 
X
 
X
 
6
 
5
 
20
 
mg/kg
 
IV
 
-
 
X
 
X
 
X
 
7
 
5
 
5 mg/kg SC
 
2000 U/mL
 
X
 
 
 
8
 
5
 
20 mg/kg SC
 
2000 U/mL
 
X
 
 
 
Total
 
32*
 
*
 
The expected enrollment is 
 
32
 
subjects.  Enrollment up to a total of 40 
subjects is permitted if additional subjects are necessary for safety or PK 
evaluations.
 
IV = Intravenous; SC = subcutaneous
 
Note:
 rHuPH20 
and N6LS 
are
 m
ixed 
and administer
e
d by [CONTACT_350763]. The dose of 
rHuPH20
 
is 
2000
 U
nits per mL relative to the N6LS dose volume
.
 
 
Study 
Duration:  
 
Study participation will 
be 
approximately 
24 weeks 
for subjects in Groups 1 to 4
, 
7 and 8; 
and 
[ADDRESS_839611]: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
13
 
of 
73
 
 
STATEMENT OF COMPLIANCE
 
 
The trial will be carried out in accordance with International Council on Harmonisation Good 
Clinical Practice (ICH GCP) and the following: 
 
•
 
[LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to cl
inical studies (45 
CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812) 
 
National Institutes of Health (NIH)
-
funded investigators and clinical trial site staff who are 
responsible for the conduct, management, or oversight o
f NIH
-
funded clinical trials have 
completed Human Subjects Protection and ICH GCP Training.
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will 
be submitted to the Institutional Review Board (IRB) for review an
d approval.  Approval of both 
the protocol and the consent form must be obtained before any participant is enrolled.  Any 
amendment to the protocol will require review and approval by [CONTACT_52590].  In addition, a
ll changes to the consent form will be IRB
-
approved; a 
determination will be made regarding whether a new consent needs to be obtained from 
participants who provided consent, using a previously approved consent form.
 
 
Product: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
14
 
of 
73
 
 
1.
 
I
NTRODUCTION
 
 
1.1.
 
N6LS 
Background
 
The human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) has 
remained a major global public health problem since the discovery of the virus in 1983. Reports 
by [CONTACT_100389]/AIDS (UNAIDS) estim
ate that 
76.[ADDRESS_839612] been infected with HIV since the start of the epi[INVESTIGATOR_901]
, contributing to 35 million 
deaths 
from AIDS
-
related illnesses
 
[1]
. Despi[INVESTIGATOR_100368], global incidences of new HIV 
infections have actually declined from pe
a
k rates in the mid
-
1990s
; a 
reduct
ion attributed in part 
to increased availability of antiretroviral therapy (ART) and the effective execution of 
prevention
/
treatment programs such as those that target mother
-
to
-
child transmission.   
Unfortunately HIV 
infection 
is extremely complex and non
e of the current therapeutic 
or 
prophylactic 
regimens can
 
completely 
prevent or cure an
 
infection or induce a full recovery of 
the host immune system. Th
us, 
novel prevention and cure strategies are being investigated.
 
The VRC
/
NIAID is investigating clinica
l applications of broadly
-
neutralizing human 
monoclonal antibodies
 
(bNAbs)
 
that bind
 
the 
HIV
-
1 envelope protein 
[2
-
5]
.
 
Such antibodies 
block infection of target cells 
in vitro
, and have been shown to prevent infection of non
-
human 
primates
 
(NHP)
 
in 
in vivo
 
models for HIV 
[6
-
8]
.
Through advances in B
-
cell immunology 
utilizing 
single
-
cell cloning methods, next
-
generation sequencing, high throughput 
computational analysis techniques, and increased cell culture survivability p
rocedures
,
 
an 
extensive group of HIV
-
[ADDRESS_839613] been isolated. These include antibodies 
with 
specificities 
to 
the CD4 binding site (
VRC01 
[9]
, VRC07
-
523LS 
[5]
, 3BNC117 
[10]
)
;
 
the high
-
mannose 
patch
 
(10
-
1074 
[11]
, 
PGT121 
[12]
)
;
 
the V2 apex (
PG9 
[13, 14]
, PGDM1400 
[12]
,  CAP256.25 
[15]
)
;
 
and 
the 
membrane
-
proximal external region (
10E8
 
[3, 16]
)
.  
A
nother
 
H
IV
-
1 specific 
bNAb identified as 
N6 
was
 
recently
 
isolated 
from a patient with a 21
-
year known history of 
HIV
-
1 infection
 
that was 
control
led 
in the absence of 
ART
 
[2]
. 
 
N6 
was 
characterized 
for IgG ge
rmline identity, recombination, and somatic hypermutation 
changes
,
 
and compared 
extensively 
to 
other
 
HIV
-
1
 
bN
Abs 
for epi[INVESTIGATOR_9230]/paratope mappi[INVESTIGATOR_629576]
 
[2]
.  
Analyses showed N6 belongs to the VRC01 class of 
CD4 binding site
-
directed bNAbs, which block HIV
 
infection by [CONTACT_629601]4. VRC01 and many members of the VRC01 class are broadly cross
-
reactive, however N6 is the best in class to date 
[2]
. N6 
employs two novel mechanisms 
to 
achieve unprecedented breadth and potency.  First, 
the 
angle 
at which N6 binds to the CD4 
molecule 
is tilted 
relative 
to other 
M
Abs
 
in 
this 
class
, 
 
enabling it to 
retain robust binding 
regardless of changes in the adjacent HIV env
elop
 
V5 loop
 
(
a region 
known 
to cause steric 
clashes
, 
decreased binding capacity
, 
and 
reduced 
neutralization breadth and potency
)
.  Secondly, 
mutations in the variable gp120 V5 loop 
that 
may 
diminish 
N6 
contact
 
[CONTACT_629602] D loop 
mediated by
 
[CONTACT_629603]
.  
Moreover, 
c
omparison ribbon structures of N6 and VRC01
 
show 
 
how 
mutations 
and insertions in HIV
-
[ADDRESS_839614] certain HIV isolates
 
are resolved by [CONTACT_629604] 
N6
 
[2]
.  
 
In order to improve the pharmacokinetics of N6, t
wo amino acid substitutions 
(
methionine to 
leucine and an asparagine to serine 
M428L/N434S, 
that 
collectively
 
yielded
 
N6
LS) 
were 
Product: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
15
 
of 
73
 
 
introduced within the C
-
terminus of the heavy chain constant region of N6 via
 
site
-
directed 
mutagenesis
 
to increase its binding affinity for the neonatal Fc
-
receptor (FcRn)
. 
Incorporation of 
the LS
 
mutation
s
 
did not a
ffect t
he neutralization breadth or potency of N6LS compared to N6
 
[2]
. 
Based on
 
preclinical and clinical 
studies 
of 
passively administered 
VRC01LS and VRC07
-
523LS
 
[8, 17, 18]
, the LS 
modification is expected to result in enhanced rec
irculation and longer 
plasma half
-
life of N6LS
 
relative 
to the wild
-
type Ab.
 
N6LS is being developed 
for the prevention of HIV
-
[ADDRESS_839615]
-
in
-
human study to 
evaluate 
the safety, tolerability, and pharmacokinetics of this antibody. 
 
1.2.
 
Recombinant Human Hyaluronidase PH20 (rHuPH20
) 
 
R
ecombinant human hyaluronidase PH20 (rHuPH20)
 
enzyme 
optimize
s
 
the SC delivery of co‐
administered therapeutics by [CONTACT_629605] (
HA
)
 
in the extracellular matrix of the 
SC space that normally serves to restrict bulk fluid flow. 
ENHANZE
TM
 
Drug Product (EDP
) is 
an investigational ready to use injectable drug product that contains 1 mg/mL (110,000 U/mL) 
recombinant human hyaluronidase PH20 (rHuPH20). 
rHuPH20 
is the active ingredient of 
the 
commercial product
 
H
ylenex
®
 
recombinant
 
(hyaluronidase human injection
), hereafter refer
red
 
to as HYLENEX
 
(
150 U/mL of
 
rHuPH20
)
, which 
has been FDA
-
approved since [ADDRESS_839616] 
dosages/dose volumes. 
 
Published reports have shown additional beneficial effects of rHuPH20 when co
-
administered 
with a 
therapeutic
 
agent (antibody, protein)
,
 
such as improved absorption, incr
eased 
bioavailability, 
and 
reduced
 
pharmacokinetics (PK) 
variability of certain 
agent
s
 
[19, 20]
.  
Importantly, the 
local permeability barrier 
tissue changes induc
ed by [CONTACT_350767]20 are reversible 
within 24
-
48 hours after administration, without any inflammatory or histological changes
 
[21]
. 
 
This Phase [ADDRESS_839617] to evaluate the safety, tolerability, and pharmacokinetics of 
N6LS coadministered with 
rHuPH20
 
by [CONTACT_629606].  
 
1.3.
 
Nonclinical Experience 
 
1.3.1.
 
N6LS
 
The N6
/
N6LS antibodies 
ha
ve
 
been evaluated in pseudovirus neutralization assays
 
to assess f
or 
breadth and potency
 
against Clades A, B, C, and AG viruses
;
 
lipid and
 
tissue cross
-
reactivity 
studies to assess for binding to antigenic determinants in 
a full panel of normal human and 
Sprague
-
Dawley rat tissues and selected tissues from 
neonatal human donors
; 
and 
proof
-
of
-
concept immunotherapy studies of 
SHIV
-
infected rhesus macaques
. 
Results showed 
N6 
demonstrated superior neutralization and breath 
when assessed in parallel comparisons 
with 
a 
panel
 
of 
HIV
-
specific bNAbs. 
Specifically, 
N6
 
was able to neutrali
z
e 98%
 
of
 
viruses within a 
181
-
ps
e
udovirus 
panel 
at an IC
50
 
threshold
 
of 50 
mcg
/mL and 
9
6
% at an 
IC
[ADDRESS_839618]: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
16
 
of 
73
 
 
mc
g/mL
.
 
N6 neutralized 16 of 20 VRC01
-
resi
s
tant pseudoviruses, further demonstrating its 
extraordinary 
neutralization breadth and potency
 
[2]
. Additionally, N6 neutralized 98% of 
pseudoviruses in an extended panel of 173 clade C pseudoviruses at an IC
50
 
<50 mcg/mL and a 
median IC
50 
of 0.066 mcg/mL
.
  
 
L
ipid or tissue cross reactivity 
(TCR) 
studies have 
not
 
show
n
 
any strong evidence 
of 
toxicologically relevant 
self
-
reactivity. 
M
inimal binding of N6LS to cardiolipin
 
and mild 
reactivity with Hep
-
[ADDRESS_839619] a prolonged activated thromboplastin time when compared to 
positive and negative controls
. 
A 
single Good Laboratory Practice (GLP) 
TCR stud
y
 
using 
a 
full 
panel 
of 
normal human and Sprague
-
Dawley rat tissu
es and selected tissues from neonatal 
human donors 
showed only limited 
staining 
with N
6LS
: 
extracellular staining in vascular smooth 
muscle of the walls of hyalinized vessels in the human uterus and cytoplasmic staining in the 
root sheath of hair follicles
 
in rat skin
. 
No membrane specific binding was observed suggesting 
that there is no cross
-
reactivity of
 
toxicologic concern. 
Overall, the cumulative N6LS binding 
profile to the antigenic determinants examined closely resembles that elicited by 
[CONTACT_33807]01 
cl
ass of HIV
-
1 bNAbs.
 
 
 
Passive immunization of chronically 
simian
-
human immunodeficiency virus 
(
SHIV
)
-
infected 
rhesus macaques with N6L
S
 
resulted in transient viremia control, the extent and duration of 
which appeared to correlate with N6LS plasma levels
 
an
d baseline 
plasma viremia level
s 
before 
N6LS treatment
.
 
A 
repeat dose 
single GLP toxicology
 
study in male and female Sprague
-
Dawley 
r
ats was 
conducted to assess the safety of 
three
 
repeat
-
dose 
administrations, 10 days apart of 
N6LS at 
three dose
-
levels (4, 40, or 400 mg/k
g
) 
intravenously 
or at two dose
-
levels (
5
 
or 
5
0 mg/kg)
, 
subcutaneously
 
and to evaluate
 
the
 
toxicity and reversibility
 
of 
adverse 
effects after a 
[ADDRESS_839620] 
exposure to measure N6LS levels after passive immunization with
 
low and high IV and SC 
antibody 
dosages
. 
Please refer to 
the Investigator’s Brochure
 
(IB) 
for additional information
.
 
1.3.2.
 
rHuPH20
 
T
he 
specific 
nonclinical 
pharmacology, 
pharmacokinetic
,
 
and toxicity studies evaluating 
rHuPH20 are summarized in the rHuPH20 IB
, 
Section [ADDRESS_839621]
s
 
by [CONTACT_315108] 
1
2
 
subjects 
by [CONTACT_33265]. Unsolicited AEs were reported by 16/
2
6
 
(
62
%) subjects that received N6LS, with
 
the 
most frequent events of 
upper respi[INVESTIGATOR_1092] (URTI) reported by 6 subjects
 
(2
3
%)
 
and
 
diarrhea reported 
by 4 subjects
 
(15%)
. All unsolicited events were mild or moderate in 
Product: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
17
 
of 
73
 
 
severity except for one grade 3 diarrhea that began 4 days after administration, spontaneously 
resolved 2 days later, and was determined to be possibly related to N6LS.
 
 
Solicited systemic symptoms were reported in 4/14 (29%) subjects following IV administration 
and 3/12 (25%) subjects following SC administration. Symptoms reported after IV 
administration included 4 events of mild headache, 1 mild event each of malaise, 
chills, and 
nausea.  Symptoms reported after SC administration included 1 mild event each of malaise, 
myalgia, headache, and nausea. No fevers occurred after IV or SC administration.
 
Solicited local symptoms reported included
 
moderate bruising (1/14
 
subjec
ts
, 7%)
 
following IV 
administration
. Solicited local symptoms after 
SC
 
administration included
 
mild pain/tenderness 
(
9
/
1
2
 
subjects, 
75
%), mild to moderate swelling (
4
/
1
2
 
subjects, 
33
%), m
ild to severe 
redness 
6
/
12
 
subjects, 
50%
), and mild pruritus (
3
/
1
2
 
subjects, 
25
%).
 
 
A study pause occurred on 7/23/[ADDRESS_839622] reporting period. 
A 
G
roup 7 
(5 mg/kg SC N6LS + 2000 U rHuPH20/mL) 
subject
 
developed injection site erythema 
to a maximum diameter of 13 cm 
which
 
resolv
ed
 
after 30 days. A
 
Group 8
 
(20 mg/kg SC N6LS 
+ 2000 U rHuPH20/mL)
 
subject 
developed injection site erythema to a maximum of 20 cm 
wh
ich
 
resolv
ed
 
after 7 days. Since the epi[INVESTIGATOR_13368] 3 erythema observed in both individuals 
were well tolerated, not accompanied by [CONTACT_629607], and resolved without clinical se
quelae, the erythema was 
judged to not represent an increased safety risk for study participants. 
Therefore, 
the study pause 
was lifted
 
on
 
7/28/2021
. 
In addition, the PSRT determined that the protocol would not need to be 
paused for future events of the 
same type and severity.
 
 
 
Data cleaning and analysis 
are currently
 
ongoing for 
G
roups 7 and 8
 
in preparation 
for
 
the 
database lock
. 
 
Additional clinical experience is derived from o
ther bNAbs 
such as VRC01, VRC01LS,
 
and 
VRC07
-
523LS,
 
with reactivity to the 
CD4
-
binding site of the HIV envelop protein and 
administered at the same doses, dose
-
schedules, and routes proposed 
in 
this study 
in healthy 
adults
 
[9, 18, 22, 23]
. 
Overall, 
Phase [ADDRESS_839623] shown they are
 
generally well
-
tolerated, with no deaths or serious adverse events 
assessed as related by [CONTACT_629608].
 
L
ocal reactogenicity 
o
bserved
 
with IV administration of 
CD4
-
binding site 
mAbs 
to adults has includ
ed pain/tenderness, bruising, swelling, and localized erythema at the 
site of infusion that resolved within a few minutes to a few hours after the administration. 
Most 
participants
 
reported no
 
systemic
 
reactogenicity
 
symptoms with VRC01 IV administration;
 
when 
observed, 
systemic solicited 
symptoms
 
were of 
mild or moderate severity,
 
started [ADDRESS_839624] and lasted 1
-
2 days, 
with
 
malaise/fatigue,
 
myalgias,
 
headaches
 
and mild nausea 
being
 
most
 
common.
 
There have been no severe solicited reactogenicity 
symptoms related to VRC01 IV injections.  
 
SC
 
administration of 
CD4
-
binding site mAbs 
has been well tolerated in adults and infants.  Most 
study participants had either no local reactogenicity or  local s
ymptoms limited to 
injection site 
pain 
and/or tenderness, redness, and mild localized pruritus (itchiness)
.
 
Most
 
local symptoms 
resolve within 
the first
 
days after product administration. 
In some cases moderate to severe 
erythema
 
at the injection site
 
have
 
last
ed
 
up t
o
 
six
 
weeks 
post product administration
 
before 
resolv
ing
 
without clinical sequelae. 
 
Product: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
18
 
of 
73
 
 
Preliminary N6LS PK data showed the maximum serum concentrations (Cmax
) occurred within 
the first few hours after IV administration, and approximately 6 days following SC 
administration. The mean (±SD) Cmax values after a single administration of N6LS were 28±10 
µg/mL for the 5 mg/kg SC dose, 101+23 µg/mL for the 5 mg/kg IV 
dose, 589±236 µg/mL for 
the 20 mg/kg IV dose, and 1717±51 µg/mL for the 40 mg/kg IV dose. 
 
Preliminary mean (±SD) C
28D
 
serum concentrations after the first administration of N6LS were 
15±6.1 µg/mL, 32±2.3 µg/mL, 96±25.4 µg/mL, and 43±1.3 µg/mL for 
the 
5 mg
/kg SC, 5mg/kg 
IV, 20 mg/kg IV, and 40 mg/kg IV
 
doses
, respectively
.
 
1.4.2.
 
rHuPH20
 
As of 
December [ADDRESS_839625]
-
marketing Phase 4 
studies
. 
In partnered trials with co
-
administered therapeutics, more than 9000 subjects were 
exposed. 
Individual doses of rHuPH20 ranged from 15 to 96,000 U
 
(See rHuPH20 IB, section 
5.1)
.
 
 
Across all Halozyme
-
sponsored studies, SC injections of rHuPH20 have been 
well
-
tolerated in 
healthy subjects, dehydrated pediatric subjects, hospi[INVESTIGATOR_629577], subjects with 
type 1 and 2 diabetes, and subjects with rheumatoid arthritis. SC injections of rHuPH20 alone or 
in combination with hydration fluids (La
ctated Ringer’s, normal saline), co
-
injected small 
molecules (morphine, ceftriaxone, ondansetron), peptides (insulin, and insulin analogs), and  
proteins (IgG and adalimumab) have been well
-
tolerated in all clinical trials 
[21, 24]
. Most AEs 
were mild, transient injection site reactions, including erythema, pain, bruising, pruritus, burning, 
tenderness, edema, induration, irritation, paresthesia, numbness, and rash. Moderate 
injection site 
reactions, which have occurred less frequently, include burning, erythema, pain, and numbness. 
Mild
-
to
-
moderate headache was also commonly reported.
 
rHuPH20 is currently co
-
formulated with 
four
 
approved 
anticancer therapi[INVESTIGATOR_014], trastuzumab 
(
HER
CEPTIN HYLECTA
TM
/
Herceptin
®
 
SC) 
PHESGO
TM
 
(pertuzumab/trastuzumab), Darzalez 
FASPRO
TM
 
(daratumumab), 
and rituximab (i.e.
,
 
RITUXAN HYCELA
®
/RITUXAN
® 
SC/MabThera
®
 
SC) and dosed sequentially with human immunoglobin to treat primary 
immunodeficiency (HyQvia
®
/HYQ
VIA
®
).
 
1.5.
 
Rationale for 
the Study
 
Design
 
Animal and 
in vitro
 
models of HIV infection have suggeste
d 
bNAbs
 
reactive 
to
 
antigenically 
diversifi
ed Env proteins expressed by [CONTACT_629609]
/or
 
therapeutic agents to thwart the 
subversive 
effects of 
HIV
 
on the immune system
.
 
N6
LS
 
can mediate extraordinary breadth and potency
 
against 
various HIV isolates, including
 
strains 
traditionally resistant to 
other 
antibodies 
in 
this clas
s. 
Moreover, 
its
 
potency 
may indicate 
less antibody 
is required 
to mediate an effect
, offering 
the 
possibility of subcutaneous administration
 
as a 
more feasible approach to immunoprophylaxis.
 
The introduction of the LS site
-
directed mutation to increase Fc
Rn binding affinity is postulated 
to result in increased
 
antibody
 
half
-
life and persistence at 
biologically 
higher concentrations in
 
the plasma, as was shown for 
VRC01LS and VRC07
-
523LS 
[
8, 17, 18]
. 
 
 
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.[ADDRESS_839626]
-
in
-
human trial to evaluate the safety of 
a 
single- or 
three, repeat
-
dos
e 
regimen
 of 
N6
LS
 
administered intravenously
 or subcutaneously. The study will also evaluate the 
feasibility of 
larger SC dose volumes (>2.5 mL) 
of N6LS administration facilitated by [CONTACT_350767]20
. 
The dos
ages
 
selected 
for evaluation 
of N6LS 
are based 
on 
prior experience with 
another 
CD4
-
binding site antibody VRC01, which was shown in two clinical trials (VRC 601 and VRC 602 
[22, 23]
) 
to be safe and well
-
tolerated 
at
 5-
40 mg/kg dosages 
given 
intravenously and at 
a 
5 
mg/kg dosage given subcutaneously in both HIV-
infected 
and 
-uninfected adult populations.  
While 
Groups 1 through 4 will receive a s
ingle
 dose of N6LS by 
[CONTACT_629610], 
Groups 5 and 6 
will be administered three
-
repeat doses
 
of N6LS
 
at 
12-week interval
s (i.e., 
on 
Weeks 0, 12, and 24). 
A 
12-
week interval 
for repeat
-dosing 
has been used in clinical trials with 
VRC01LS 
[18] 
and VRC07
-523LS [25]. Groups 7 and 8 will receive a single 5 or 20 mg/kg dose 
of N6LS co
-
mixed
 
with 
rHuPH20
 by [CONTACT_350763] 
(Refer to the 
pharmacy manual
 
for 
stu
dy 
product preparation and administration instructions).  
Aligning
 the antibody dose levels and 
administration inter
val with th
at 
used in the current and 
prior 
studies 
with 
other 
HIV
-[ADDRESS_839627] comparison of 
the 
serum concentration
 of each bNAb 
at identical time
-
points. This in turn will support pharmacokinetic (PK) profile comparisons 
and character
ization 
of the bNAbs currently in development by [CONTACT_33807]. The PK of N6LS administered using 
different regimens, dosages, and routes is 
also 
being evaluated in healthy adults aged [ADDRESS_839628] rather than assess the health of the subjects. Laboratory assessments in this Phase 1 study 
will include 
PK analysis, evaluation 
for anti
-
drug antibody (ADA) development following 
product exposure, and 
ex vivo analysis to assess the 
neutralization 
activity 
of N6LS post-
injection/
infusion.  
The VRC’s Vaccine Immunology Program (VIP), Gaithersburg, MD, will process blood and 
store coded samples, and will eit
her perform sample testing or ship coded samples to designated 
research laboratories at the VRC or other approved collaborators.  Some immunogenicity assays 
may be performed by [CONTACT_100392], MD, or by [CONTACT_100393].  See 
Appendix I
 for schedules, volumes and tube types to be used for 
research sample collection.  Tube types for clinical laboratory evaluations and research 
collections are selected according to institutiona
l requirements and are shown in the Schedule of 
Evaluations to estimate blood volumes.  Different tubes may be used to meet site requirements. 
Samples will be transported according to approved site procedures.
 
1.6.1.
 
Pharmacokinetic 
(PK) Analysis 
 
The 
N6LS concen
tration for the PK analysis will be measured by a 
Meso Scale Discovery 
(MSD) or similar assay
 [22]. 
1.6.2.
 
Anti
-
drug Antibody (ADA) A
nalysis  
A three
-
level algorithm will be used to screen, confirm, and functionally characterize ADA 
to 
N6LS 
and rHuPH20 in 
clinical serum
 and plasma 
samples 
collected at 
baseline (day 0), Week 4 
(Day 28), and Week 8 (Day 56) for groups 1-4, and Groups 7-8.  For groups 5-
6, ADA is 
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.0  
 
October 07
, 2022 
 
 
Page 
20
 
of 
73
 
 
analyzed at baseline (Day 0), Week 4 (Day 28), Week 28 (Day 196),  and Week 32 (Day 224).  
Analysis will be conducted according to the Food and Drug Administration (
FDA
) guidance 
[26]. Screening and confirmation will involve 
a Meso Scale Discovery (MSD) 
electrochemiluminescence (ECL) bridging or similar
 
assay
 
[22
].   
Tier 1 and 2 N6LS ADA assays are qualified and method development to functionally 
characterize ADA activity in clinical serum samples that also contain N6LS (tier 3 assay) is 
ongoing and not presently available. However, the stored 
clinical serum samples will be tested 
once the assay is qualified
.  
1.6.3.
 
HIV Ps
eudovirus Neutralization  
 
For all study groups, s
ubject sera 
collected 
(but not limited to) at baseline (
Day
 0), [ADDRESS_839629]-
administration, and at Day 84 
may be evaluated to asse
ss the 
functional capacity of 
passively 
administered 
N6LS 
to neutralize 
pseudotyped HIV viruses using an 
in vitro
 
cell
-based virus 
neutralization assay
 
such 
as previously described for VRC01, VRC01LS, and VRC07-523LS  [2, 
22, 23, 25, 27].  
1.6.4.
 
Allotype
-
specific Effects
 
Exploratory evaluation  to detect for theoretical 
immunoglobulin G1 (
IgG1
) 
allotype
-
specific 
effects may be performed in cases when PK measures suggest a reduced N6LS antibody half
-
life 
or an ADA response [28-30]. Coded stored samples will be used for evaluation of the genetic 
sequence of the immunoglobulin heavy chain constant region allotype.  
 
 
Product: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
[ADDRESS_839630]
S
 
This protocol 
will evaluate
 
the use of two investigational products: the antibody N6LS and 
rHuPH20, the active pharmaceutical ingredient in EDP. A summary of the manufacturing 
process for N6LS is provided in this section. Please refer to the rHuPH20 IB, 
Section 
[ADDRESS_839631] 
preparation and administration guidance
. 
 
2.1.
 
N6LS 
(VRC
-
HIVMAB091
-
00
-
AB) 
 
2.1.1.
 
Overview
 
The N6LS antibody binds to the CD4
-
binding site of HIV
-
1 gp120 protein and 
contains a 
methionine to leucine (L) and asparagine to serine (S) (M428L/N434S, referred to as 
(
LS) 
change within the C
-
terminus of the heavy chain constant region to increase its binding affinity 
for the neonatal Fc
 
receptor (FcRn)
 
[31]
. 
The 
antibody is expressed as a recombinant IgG1 
antibody in a Chinese Hamster Ovary (
CHO) mammalian 
cell line
, CHO
-
DG44, and is 
manufactured under current Good Manufacturing Practices (cGMP) by
 
[CONTACT_33805]/NIAID/NIH
 
at the 
VRC Pi[INVESTIGATOR_629578], Leidos 
Biomedical Research, Inc., Frederick
, MD.  Specific manufacturing information is included in 
the 
IB
. Quality Assurance (QA) lot release testing by [CONTACT_629611], and 
during conduct of the clinical trial. 
 
2.1.2.
 
Manufacturing and Drug Product Production 
 
Drug substance
 
(DS)
 
i
s manufactured 
under cGMP
 
using a stable transfected 
CHO
-
DG44 
cell 
line. Purification steps include an initial harvest by [CONTACT_381296]
-
based cl
arification and 
diafiltration into
 
chromatography buffer
, followed by [CONTACT_109414]
-
A affinity c
hromatography
, low pH 
treatment of the eluate, and 
anion exchange membrane chromatography
. The eluate is 
then 
subjected to 
a 
20 nm virus reduction filtration step, fo
llowed by 
[CONTACT_629612]
, prior to filtering with a
 
0.22 μm
-
filter
. The DS 
concentration 
is 
determined
 
and 
fill
ed 
into containers
 
for storage 
at ≤ 
-
65°C until 
further formulation is required. 
 
 
The 
N6LS DS
 
is
 
diluted 
to 
a 
concentration of 
100 mg/mL in 
formulation buffer 
composed of 10 
mM Sodium Citrate, 50 mM Sodium Chloride, 150 mM Arginine
-
HCl, and 0.002% Polysorbate
-
80 (PS
-
80) at pH 6.[ADDRESS_839632] (D
P
)
. The product 
is 
filled 
i
nto 
10 mL 
single
-
use 
glass 
vials 
at a concentration of 100 ± 10 mg/mL and vo
lume of 6.25 ± 0.[ADDRESS_839633] (
DP
)
 
should be stored at 
-
35°C to 
-
15°C.
  
 
More details on the N6LS composition and manufacturing can be found in the IB.
 
2.2.
 
ENHANZE
TM
 
Drug Product (EDP)
 
Recombinant human hyaluronidase PH20 (rHuPH20) is the active ing
redient of the 
investigational ENHANZE™ Drug Product (EDP). rHuPH20 is produced by [CONTACT_629613] (CHO) cells containing a deoxyribonucleic plasmid encoding 
a soluble fragment of human hyaluronidase PH20. The purified hyaluron
idase glycoprotein 
contains [ADDRESS_839634]: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
22
 
of 
73
 
 
EDP
,
 
manufactured 
by
 
[CONTACT_350783], Inc. (San Diego, CA)
 
for Halozyme, Inc. (San Diego, 
CA)
,
 
is a purified preparation of rHuPH20
 
supplied in 
glass 
vials as a
 
sterile, 
clear, colorless, 
non
-
preserved, ready
-
for
-
use
 
solution
. Each mL contains
 
~110 kU
 
of 
rHuPH20
. The solution has 
a pH of approximately 6.5 and contains 130 mM sodium chloride, 10 mM L
-
histidine 
hydrochloride as a
 
buffer,
 
and 10 mM L
-
methionine,
 
0.02% w/w PS80. The solution is filled to 
0.5 mL in a 2 mL glass vial and 
should 
be stored 
as labeled, either at 
-
20°C ± 5°C or 5°C ± 3°C
 
and protected from light
.
 
More details on rHuPH20
 
and EDP
 
are provided 
in the rHuPH20 IB
 
(
Edition 
10
.0, 
February 04, 
2022
)
.
 
 
 
Product: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
23
 
of 
73
 
 
3.
 
STUDY OBJECTIVES 
 
3.1.
 
Primary 
O
bjective
s
 
•
 
To evaluate the safety and tolerability of N6LS administered as a single dose at 5 
mg/kg IV, 20 mg/kg IV, 40 mg/kg IV, 
or
 
5 mg/kg SC to healthy adults.
 
•
 
To evaluate the safety and tole
rability of N6LS administered at 5 mg/kg SC
 
or
 
20 
mg/kg IV 
by [CONTACT_128169] 12 weeks for a total of 3
 
injections/
infusions in 
healthy adults.
 
•
 
To evaluate the safety and tolerability of a single 5 or 20 mg/kg SC dose of N6LS 
coadministered with 
rHuPH2
0
 
in healthy adults.
 
3.2.
 
Secondary 
O
bjective
s
 
•
 
To evaluate the pharmacokinetics of N6LS at each dose level
 
through [ADDRESS_839635] dose
.
 
•
 
To determine whether anti
-
drug antibody (ADA) to N6LS can be detected in 
sera of
 
N6LS recipi[INVESTIGATOR_629579]
.
 
3.3.
 
Exploratory 
O
bjectives
 
•
 
To evaluate for evidence of functional activity of 
N6LS
 
in samples collected
 
during 
the study at specific timepoints
.
 
•
 
To 
assess 
for IgG1 allotypes 
by 
[CONTACT_940] (
PCR
)
 
and 
evaluate 
for 
allotype
-
specific effects on 
N6LS
 
pharmacokinetics.
 
 
 
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.0  
 
October 07
, 2022 
 
 
Page 
24
 
of 
73
 
 
4.
 
STUDY DESIGN AND CLINICAL PROCEDURES
 
This is an open
-
label, dose
-escalation study to examine the safety, tolerability, dose, and PK of  
N6LS in healthy adults. As shown in the study schema 
in
 
Table
 1
, s
ubjects 
in Groups 1 to 4 
will
 
receive 
a single dose of N6LS at the 5, 20, or 40 mg/kg dose level; subjects in Groups 5 and 6 
will receive repeat dosing of N6L
S every 12 weeks for a total of 3 injections at the 5 mg/kg dose 
level 
or 
3 
infusions at 
the 
20 mg/kg dose level
, respectively
; 
subjects in Groups 7 and 8 will 
receive a single dose of N6LS at the 5 mg/kg and 20 mg/kg dose level (respectively) co-
administered with rHuPH20 (2000 U/mL) vi
a SC infusion.  
If enrolled into 
Groups 1
, 4, 7 and 8 subjects 
will be expected to be available for follow
-up visits 
through 24 weeks of study participation. Subjects enrolled into Groups 5 and 6 will be expected 
to be available for follow
-up visits through 48 weeks of study participation. 
Table
 
1
:
 
VRC 609 Study Schema
 
Group
 
Subjects
 
Study Products
 
Dosing  
Schedule
 
N6LS 
Dose 
and Route
 
 
rHuPH20
 
Dose
 
Day 
0
 
Week 12
 
Week 24
 
1 
3 
5 
mg/kg IV
 
- 
X 
 
 
2 
3 
5 
mg/kg SC
 
- 
X 
 
 
3
 
3
 
20
 
mg/kg IV
 
-
 
X
 
 
 
4 
3 
40 
mg/kg IV
 
- 
X 
 
 
5 
5 
5 
mg/kg
 
SC
 
- 
X 
X 
X 
6 
5 
20 
mg/kg
 
IV
 
- 
X 
X 
X 
7 
5 
5 
mg/kg
 
SC
 
2000 U/mL 
X 
 
 
8 
5 
20 
mg/kg
 
SC
 
2000 U/mL 
X 
 
 
Total
 
32
* 
* 
A total of 
 
[ADDRESS_839636] 
subjects
 
who
 
fail to 
complete
 
the
 
assigned dosing regimen and 
to 
meet requests for 
additional pharmacokinetic (
PK)
 
and/or new safety
 
evaluations.
 
IV = Intravenous; SC = subcutaneous
 
Note:
 
rHuPH20 and N6LS are mixed and administered by [CONTACT_350763]. The dose of rHuPH20 is [ADDRESS_839637] preparation and 
administration instructions
. 
 
 
Enrollment beg
an
 
with 
the 5 mg/kg dose groups (Groups 1
, 2,
  and 5) when the protocol opened 
to accrual
. Enrollments into the subsequent dose groups (Groups 3, 4, and 6) proceed
ed
 
after 
dose-
escalation reviews as described in
 
Section 4.3
. 
With implementation of the two N6LS+
 
rHuPH20
 groups as a protocol amendment, Group [ADDRESS_839638] 
administration before
 
the same dose and administration route
 of 
N6LS is administered to 
additional subjects
.  Safety review decisions and the status of the enrollment p
rocess will be 
transparent to the Protocol Safety Review Team (PSRT) 
throughout the trial and discussed 
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.0  
 
October 07
, 2022 
 
 
Page 
25
 
of 
73
 
 
during the weekly and/or monthly 
safety review.
 The composition of the PSRT is discussed in 
Section 8.8
. 
Safety
 laboratory 
samples will
 
be
 
collected
 throughout the study as per the Schedule of 
Evaluations 
(SOE)
 shown in 
Appendix I
.  Subjects 
will
 
keep
 a 
daily
 
diary
 of 
solicited
 
systemic
 
symptoms
 
for
 [ADDRESS_839639]’s 
last
 
product 
administration.
  
The study will be conducted at the Vaccine Evaluation Clinic located a
t the NIH Clinical Center 
(NIH CC).
 
4.1.
 
Study Population
 
All inclusion and exclusion criteria must be met for eligibility.
 
4.1.1.
 
Inclusion Criteria
 
A 
subject 
must meet all of the following criteria
: 
1.
 
Willing and able to complete the informed consent 
process.
 
2.
 
[ADDRESS_839640] meet the following 
criteria:
 
•
 
White blood cell count (WBC): 2,500-12,000/mm
3
. 
•
 
WBC 
differential: Within
 
institutional normal range 
or 
accompanied by [CONTACT_9532] (PI) or designee approval
. 
•
 
Platelets: 125,000 – 400,000/mm
3
. 
•
 
Hemoglobin: Within institutional normal range
 
or accompanied by [CONTACT_976] [INVESTIGATOR_629580]. 
•
 
Creatinine: ≤ 1.1 x Upper Limit of Normal (ULN)
. 
•
 
ALT: ≤ 1.25 x ULN
. 
•
 
AST: ≤ 1.25 x ULN
.  
•
 
Negative for HIV infection by [CONTACT_178125]. 
Female
-
Specific Criteria:
 
7.
 
If a woman is of reproductive potential and sexually 
active with a male partner, then she agrees 
to use an effective means of birth control from the time of study enrollment until the last study 
visit, or to be monogamous with a partner who has had a vasectomy. 
Product: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
26
 
of 
73
 
 
8.
 
Negative β
-
HCG (human chorionic gonadotropin) p
regnancy test (urine or serum) on day of 
enrollment for women presumed to be of reproductive potential.
 
4.1.2.
 
Exclusion Criteria
 
A 
subject 
will be excluded if one or more of the following conditions apply
:
 
1.
 
Prior receipt of 
licensed or investigational 
monoclonal antibody.
 
2.
 
Weight > [ADDRESS_839641]
 
i
ncluding
 
(
but not limited to
)
: diabetes 
mellitus type I, chronic hepatitis
; 
OR
 
clinically significant fo
rms of
 
drug or alcohol abuse, 
asthma, autoimmune disease,
 
infectious disease,
 
psychiatric disorders, heart disease, or cancer
.
 
8.
 
Known hypersensitivity to hyaluronidase or any of the excipi[INVESTIGATOR_629581]
.
 
4.2.
 
Inclusion of Vulnerable Subjects
 
4.2.1.
 
Participation of Childr
en
 
Children are not eligible to participate in this clinical trial because the study agent has not been 
previously evaluated in adults.  If the product is assessed as safe for further study other protocols 
specifically designed for children may be conducte
d.
 
4.2.2.
 
Participation of NIH Employees
 
NIH employees and members of their immediate families may participate in this protocol. We 
will follow the Guidelines for the Inclusion of Employees in NIH Research Studies and will give 
each employee a copy of the “NIH FA
Qs for NIH 
Staff Who are Considering Participation in 
NIH Research 
”
 
published by [CONTACT_52610], Policy 404.
 
 
For NIH employee subjects, consent will be obtained by [CONTACT_28045] w
ho is independent of the 
employee’s team.  If an NIH staff member seeks to enroll in research taking place within their 
own work unit or conducted by [CONTACT_100404], the employee will be:
 
•
 
Informed that neither participation nor refusal to 
partici
pate
 
as a research subject will 
have an effect, either beneficial or adverse, on the subject’s employment, training or 
position at the NIH,
 
•
 
When possible, consent should be obtained by [CONTACT_100405] a non
-
supervisory
 
relationship with the subject, and
 
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.0  
 
October 07
, 2022 
 
 
Page 
27
 
of 
73
 
 
•
 
When consent is conducted, a third party (e.g. a consent monitor) 
will be included 
through the Bioethics Consultation Service
 or another party independent 
of the research 
team or, if a consent monitor is not available, t
he consent process will be observed by 
[CONTACT_178127]’s 
work unit and not a supervi
sor to the NIH staff member.  If no such person exists, 
consent observation may be performed by [CONTACT_31617] q
ualified investigator on the study.
  
Protocol study staff will be trained on obtaining potentially sensitive and private 
information from co
-workers or subordinates.  
4.2.3.
 
Adult Subjects who Lack the Capacity to Consent
 
Adults who are unable to provide initial informed consent are not eligible to enroll. Also, adults 
who permanently lose the capacity to provide on-going consent after initial consent and during 
the study will be discontinued from protocol participation as it is described in 
Section 4.
[ADDRESS_839642] will 
comply with the NIH CC 
Guidelines, which is available on the NIH intranet at the following link: http://cc
-
internal.cc.nih.gov/policies/PDF/M95-9.pdf. 
4.3.1.
 
Recruitment and Retention Strategies 
 
Study enrollments 
will be conducted at the NIH Clinical Center. Stu
dy subjects will be recruited 
through the VRC’s screening protocol, VRC 500 (NCT 01375530). The on-site and off-
site 
Institutional Review Board (IRB)
-
approved advertising will be implemented. Per a recruitment 
plan described in the VRC 500 protocol, efforts 
will be made to include women and minorities in 
proportions similar to that of the community from which they are recruited.
 
4.3.2.
 
Screening
  
All 
screening 
procedures 
for this study 
are described and 
will be completed through the Vaccine 
Research 
Center’s screening protocol, VRC 500 (NIH 11-I-0164) 
used for all VRC IND studies 
conducted at the NIH Clinical Center
.  
The Recruitment Plan per NIH Policy [ADDRESS_839643] (IRB)-approved advertising.  
Screening
 evaluations 
performed to 
determine
 
eligibility for study participation
 
will include medical history review, 
physical exam, and the clinical laboratory tests
 
as
 
detailed in the S
chedule of Evaluations, 
Appendix I
)
. 
No screening procedures will be done under protocol 
VRC 
609.  
Additional assessments of health 
may
 be conducted at screening based on clinical judgment.  
Screening evaluations for specific eligibility criteria must be completed within the time interval 
specified prior to enrollment for the given parameter and may be repeated, as needed, to confirm 
eligibi
lity.  
Blood samples for research can be drawn at any time during the screening period and are not 
required to be repeated if outside the screening period. Informed consent documents will be 
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.[ADDRESS_839644], pregnancy prevention and 
HIV
 
risk
-reduction 
will be performed.  An Assessment of Understanding (AoU) will be 
completed in association with enrollment into VRC 609.  Screening records will be kept to 
document the reason why an individual was screened 
but not enrolled.  
4.3.3.
 
Enrollment
, Study Days and Visit Numbers
 
In this study, enrollment is defined as the assignment of a study identification number and study 
group schedule in the clinical database.  A clinician will discuss the target dates and timing of the 
study product administration(s) and sample collections before completing an enrollment to help 
ensure that the subject can comply with the projected schedule.  
Day [ADDRESS_839645] N6LS administration.
  
Day 0 may occur on the same day as 
enrollment or up to 6 weeks after enrollment.  This period
 may be increased with PI [INVESTIGATOR_41473].  If 
Day 0 does not coincide with enrollment, then the enrollment day may be referred to by a 
negative number of days (i.e., Day -1 to Day -42).  For calculating elapsed days following Day 0, 
each subsequent calendar date
 is labeled by [CONTACT_125557] “Study Day” as shown in the 
Schedule of Evaluations (
Appendix I
).  Since there may be more than one research sampling 
timepoint of interest per study day, each sample collection timepoint has its own “Visit 
Number.”  For this reason, there may be more than one visit number recorded on the same 
calendar date.
 
Medical history and Day [ADDRESS_839646] administration, temperature, blood pressure, heart rate (pulse) and weight 
will be 
recorded and a targeted physical examination 
will 
be conducted.  
All s
ubjects 
will be 
observed for [ADDRESS_839647] is assigned to an IV administration group, the IV access will be placed in an arm vein 
in an aseptic manner.  A different site may be used for collection of PK blood samples; however, 
the same site may be used after f
lushing the line if another site is not available.  N6LS will be 
administered with approximately 100 mL 
of 
normal saline IV (
as described in the IB
) over about 
15-[ADDRESS_839648] is assigned to a SC administr
ation group, the SC administration site(s) to be used 
must be assessed as acceptable by [CONTACT_52613].  The preferred SC administration 
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.0  
 
October 07
, 2022 
 
 
Page 
29
 
of 
73
 
 
site is the abdomen, but the upper arm or thigh may be used.  Given the weight criterion in this 
study, the maximum volume needed to administer a 5 mg/kg SC dose is not expected to exceed 
5.[ADDRESS_839649] is assigned to a SC administration group, the SC administration site(s) to be used 
must be assessed as acceptable by [CONTACT_52613].  The preferred SC administration 
site is the abdomen. 
N6LS will be mixed with 
rHuPH20
 in the ph
armacy and 
then 
administered 
via standard Medfusion 3500 
syringe pump
 
(or equivalent)
 in one infusion site 
at a rate of
 no 
more than 3 
mL/minute. Given the weight criterion in this study, the maximum volume needed 
to administer a 20
 mg/kg SC dose is not ex
pected to exceed 23.
[ADDRESS_839650] experiences 
side effects during the infusion, the rate of infusion may be slowed or stopped to alleviate the 
symptoms. 
Procedures for 
all 
N6LS preparations 
and administration
s 
are described in 
Section
 
7
.  
4.3.5.
 
Solic
i
ted 
Adverse Events and Clinical Follow
-
up
 
Subjects will be given a 3-
day diary (paper or electronic
-based), a thermometer, and a measuring 
tool
. The subjects will use the diary daily as a memory aid to record their highest temperature, 
local and systemic symptoms, and concomitant medications taken
 for [ADDRESS_839651] file for 
moni
toring purposes.
 
The signs and symptoms solicited by [CONTACT_629614]/feeling unwell, muscles aches (outside the injection site), headache, chills, nausea and joint 
pain; and local (at the product administration site) e
vents of pain/tenderness, swelling, redness, 
bruising, and pruritus. Subjects will record their highest measured temperature daily for 
assessment of fever
 and largest measured diameter of redness, swelling, and bruising at the 
injection site
.  Subject diar
ies will be reviewed by a clinician for accuracy and completeness at 
follow
-
up visits. No attribution assessment will be performed for solicited events reported in the 
diary. Clinicians will follow and collect resolution information for any reactogenicity 
symptoms 
that are not resolved within [ADDRESS_839652] is reported. 
Events that may requir
e a clinic visit include rash, urticaria, fever of 38.6˚C (Grade 2) or higher 
lasting greater than 24 hours or significant impairment in the activities of daily living (ADL) 
(such as those consistent with Grade 2 or higher impairment). Additionally, arthra
lgia or other 
clinical concerns may prompt a study visit based on the judgment of a study clinician. 
 
Clinical laboratory assays and clinical evaluations will assess safety and tolerability at specified 
intervals after each administration.  Throughout the 
study, clinicians will also assess subjects for 
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.0  
 
October 07
, 2022 
 
 
Page 
30
 
of 
73
 
 
any changes in symptoms.  Any new or concerning symptoms will be fully assessed to include 
specialty consultation at the NIH Clinical Center as indicated clinically
.  
4.3.6.
 
Pharmacokinetics  
 
PK samples will be collected as close as reasonably possible to the target timepoints.  However, 
actual time of collection is critical for PK analysis and will be recorded for all samples.  The PK 
timepoints are shown in the Schedule of Evaluations (
Appendix I
). 
4.3.7.
 
Schedule of Evaluations
 
The Schedule of Evaluations (
Appendix I
) 
provides details on the study schedule and the 
permitted visit windows.
  
Schedule 1 is for the IV dose escalation groups receiving one infusion 
(Groups 1, 3, and 4). Schedule 2 is for the SC dose group receiving one injection (Group 2).  
Schedule 3 and Schedule 4 are for the groups receiving repeat dosing: Group 5 (5 mg/kg SC) and 
Group 6 (20 mg/kg IV), respectively.
  
Schedule 6 is for the N6LS+ 
rHuPH20
 SC dose groups 
receiving one infusion at N6LS dose levels of 5 mg/kg (Group 7) or 20 mg/kg (Group 8). 
After 
enrollment, deviations from the visit windows are discouraged but will be permitted at the 
discretion of the PI [INVESTIGATOR_1461]; and will be recorded as protocol deviations.  
If product administration is discontinued for a 
Group [ADDRESS_839653] 
safety or for samp
le collection for immunological testing.  After study completion, subjects may 
be invited to participate in one of the VRC sample collection protocols (VRC 200 or VRC 900) 
for follow
-
up sample collection.
 
Any evaluation for an AE or possible exacerbation o
f a pre
-
existing condition may be evaluated 
at study team discretion as a “protocol related” evaluation
. 
4.3.8.
 
Concomitant Medications 
 
Only routine prescription medications will be entered in the database at the time of enrollment.  
Subsequently, concomitant medications associated with an 
adverse event (
AE
) 
that requires 
expedited reporting or the development of a new chronic condition re
quiring ongoing medical 
management will be recorded in the database.  Receipt of a FDA
-
approved vaccine at any time 
during the study will be recorded in the database (clinicians should work with subjects regarding 
the timing of licensed vaccines relative t
o study product administration).  Otherwise, 
concomitant medications taken throughout the study will be recorded in the subject’s chart as 
needed for general medical documentation but will not be recorded in the database.  
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.[ADDRESS_839654]
 
doses (repeat
-dosing) may be administered to 
applicable dose groups (
Table
 2
).
 
Whenever possible and as data are available, PSRT Data 
Reviews for dose
-
escalation and repeat
-dosing will be held concurrently as follows: 
   
Table
 2: 
Schema for 
Dose
-
escalation and Repeat
-
Dosing PSRT Data Reviews
 
Data Review 
 
Objective
 
Minimum Evaluable 
 
Safety Data*
 
Favorable 
 
Review Outcome
 
Review #1
 
•
 
Dose-
escalation
 
from 5 to 20 mg/kg IV
 
 
•
 
Repeat
-
dosing at 5 
mg/kg SC
 
•
 
All post
-
administration safety data from Day [ADDRESS_839655] the 
“
Day 14
” 
visit in 
at least 3
 
subjects in Group 1.  
 
•
 
A
ll post
-
administration safety data from Day [ADDRESS_839656] the 
“
Day 14
” 
visit in 
at least 3
 
subjects in Group 2 or 5.  
 
•
 
Proceed wit
h enrollments 
into Groups 3 and 6.
 
 
•
 
Proceed with second and 
third doses in Group 5.
 
Review #2
 
•
 
Dose-
escalation from 
20 to 40 mg/kg IV
 
 
•
 
Repeat
-
dosing at 20 
mg/kg IV
 
•
 
All post
-
administration safety data from Day [ADDRESS_839657] the “Day 14” visit in 
at least 3
 
subjects in Group 3 or 6.  
 
 
•
 
Proceed with enrollments 
into Group 4.
 
 
•
 
Proceed with second and 
third doses in Group 6
 
Review #3
 
•
 
Dose-
escalation
 
from 5 to 20 mg/kg 
N6LS with 
rHuPH20
 
by [CONTACT_629615]
 
•
 
All post
-
administration safety data from Day [ADDRESS_839658] the “Day 14” visit in 
at least 3
 
subjects in Group 7
 
•
 
Proceed with enrollments 
into Group 8.
 
If the first product administration is not completed or there are discontinuations from the study 
before there are sufficient data to conduct the dose escalation review, then extra subjects may be 
enrolled in order to have the requisite data on at least [ADDRESS_839659] at the time of a dose
-
escalation review may be judged by [CONTACT_629616] a given 
dose group. 
The IRB will be provided with documentation of the safety review process and notification of 
the dose-escalation.  Consultation with the IRB and 
notification of the 
FDA, if needed, as per 
study pause criteria 
(
Section
 
4.6
) will occur if indicated by [CONTACT_33828].  One outcome of a dose-
escalation review may be to recommend evaluation of additional subjects at the current dose and 
reassess for safety before proce
eding to a higher dose. 
Product: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
[ADDRESS_839660] may be discontinued from protocol participation for the following reasons:
 
•
 
Subject voluntarily withdraws;
 
•
 
The IND Sponsor or regulatory authorities stop the study; 
 
•
 
The PI [INVESTIGATOR_178104]
; or
 
•
 
Severe non
-
compliance as determined by [CONTACT_978].
 
4.6.
 
Criteria for 
Discontinuation of N6LS
 
or 
N6LS+
 
rHuPH20
 
Administration
 
Under certain circumstances, a subject may 
be prohibited from receiving further 
study product 
administrations. These include:
 
•
 
Pregnancy (female subjects only);
 
•
 
Grade 3 adverse event assessed as related to 
N6LS or N6LS+rHUPH20 
(with the 
exception that self
-
limited Grade [ADDRESS_839661] administration);
 
•
 
Grade 4 adverse event assessed as related to
 
N6LS or N6LS+
rHUPH20
; 
 
•
 
Immediate hypersensitivity reaction associated with 
N6LS or N6LS+rHUPH20
;
 
•
 
Intercurrent illness that is not expected to resolve prior to the next scheduled study 
product administration AND 
for which 
PI (or designee) 
believes is in the best interes
t 
of the subject
 
to restrict further exposure
; 
 
•
 
Repeated failure to comply with protocol requirements; 
 
•
 
Co
-
enrollment into a study 
to receive ano
ther 
investigational research product prior to 
completion of the requisite study 
follow
-
up 
following 
the last 
N
[ADDRESS_839662] 
administration;
 
•
 
The IND sponsor or the study PI [INVESTIGATOR_629582];
 
•
 
The IRB, Office for Human Research Protections (OHRP) or the FDA halt the study.
 
Subjects who have received at least one dose of N6LS but have been discontinued from
 
further 
study product administrations, will continue 
with 
follow
-
up
 
as shown in 
the Schedule
 
[ADDRESS_839663] 
(N6LS or N6LS+
 
rHuPH20
) 
and new enrollments will be 
paused by [CONTACT_978] [INVESTIGATOR_629583]: 
 
•
 
One
 
(or more) subject experiences a 
serious adverse event (
SAE
)
 
that is assessed as 
related
 
(possible, probably, or definitely)
 
to 
the 
study 
product
, or
 
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.0  
 
October 07
, 2022 
 
 
Page 
33
 
of 
73
 
 
•
 
Two
 
(or more) subjects experience the same 
Grade 3 or higher AE
 
that is
 
assessed 
as related 
(possible, probably, or definitely) to study agent (other than 
self
-
limite
d 
Grade 3 
AEs that resolve during the solicited reactogenicity
 period
).
 
In the event of a pause,
 
the IND Sponsor Medical Officer (MO) and the PSRT will be promptly 
notified.  
Plan for Review of Pauses and Resuming Rules:  
 
Study product administration and 
enrollments would resume only if review of the AEs that 
caused the pause results in a recommendation to permit further study product administrations and 
study enrollments.  The reviews to make this decision will occur as follows:
 
•
 
Pauses for related 
SAEs
: The IND Sponsor 
Medical Officer (MO)
, with 
participation by [CONTACT_978], will conduct the review and make the decision to resume, 
amend or close the study. The 
IRB 
and FDA will be notified 
accordingly.
 
•
 
Pauses for Grade 3 or higher related AEs
: The IND Spo
nsor MO, in consultation 
with the PI, will conduct the review and make the decision to resume, amend or close 
the study for the Grade 3 or higher AEs that meet criteria for pausing the study.  As 
part of the pause review, the reviewers will also advise on 
whether the study needs to 
be paused again for any subsequent events of the same type.  The FDA and the IRB 
will be notified of Grade 3 or higher pause reviews and of the IND Sponsor’s 
decisions. 
 
 
Product: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
34
 
of 
73
 
 
5.
 
SAFETY AND ADVERSE EVENTS
 
5.1.
 
Adverse Events
 
An adverse event (AE) is any untoward or unfavorable medical occurrence in a human subject, 
including any abnormal sign (e.g., abnormal physical exam or laboratory finding), symptom, or 
disease temporally associated with the use of study treatment, whether
 
or not considered related 
to the study treatment.  
 
Severity of AEs will be assessed using the
 
DAIDS Table for Grading the Severity of Adult and 
Pediatric Adverse Even
ts
, Corrected Version 2.1 [July 2017]. Available from: 
https://rsc.tech
-
res.com/docs/default
-
source/safety/division
-
of
-
aids
-
(daids)
-
table
-
for
-
grading
-
the
-
severity
-
of
-
adult
-
and
-
pediatric
-
adverse
-
events
-
corrected
-
v
-
[ADDRESS_839664] administration. After this through comple
tion of study 
participation only serious adverse events (SAEs) and new chronic medical conditions that require 
ongoing medical management will be recorded as AEs in the study database.
 
When
 
a subject who receives N6LS coadministered with rHuPH20 experience
s an AE assessed 
by [CONTACT_629617], this attribution reflects relatedness to N6LS and 
not rHuPH20. Any differences in safety and tolerability between the 5 mg/kg SC N6LS dose 
without rHuPH20 and 20 mg/kg N6LS SC dose with rHuP
H20 will be interpreted as a dose
-
response difference of N6LS delivered subcutaneously. The extant experience with rHuPH20 
indicates that rHuPH20 itself does not confer a 
unique
 
set of AEs and this protocol will not 
specifically evaluate rHuPH20 itself for
 
safety and tolerability
. 
 
5.2.
 
Serious Adverse Events
 
The term “Serious Adverse Event” (SAE) is defined in 21 CFR 312.32 as follows:  “An adverse 
event or suspected adverse reaction is considered serious if, in the view of either the investigator 
or the sponso
r, it results in any of the following outcomes:  Death, a life
-
threatening adverse 
event, inpatient hospi[INVESTIGATOR_1081], a persistent or 
significant incapacity or substantial disruption of the ability to conduct norm
al life functions, or a 
congenital anomaly/birth defect.  Important medical events that may not result in death, be life
-
threatening, or require hospi[INVESTIGATOR_708], based upon 
appropriate 
medical judgment, they may jeopardize th
e patient or subject and may require medical or 
surgical intervention to prevent one of the outcomes listed in this definition.  Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an emergency 
room or at home, bl
ood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], 
or the development of drug dependency or drug abuse.”
 
“Life
-
threatening” refers to an AE that at occurrence represents an immediate risk of death to a 
subject. 
It does not inclu
de an adverse event or suspected adverse reaction that, had it occurred in 
a more severe form, might have caused death.
 
Similarly, a hospi[INVESTIGATOR_355524] a SAE. 
 
Product: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
[ADDRESS_839665] be reported and submitted by [CONTACT_100409], VRC/NIAID/NIH, according to Sponsor guidelines as follows: 
 
•
 
Results in death
 
•
 
Is life threatening
 
•
 
Results in persistent or significant disability
/incapacity
 
•
 
Requires unplanned inpatient hospi[INVESTIGATOR_6929]
 
•
 
Is a congenital anomaly/birth defect in the offspring of a study subject
 
•
 
Is an important medical event that may jeopardize the subject or may require 
inter
vention to prevent one of the other outcomes listed above. 
 
In addition, any event, regardless of severity, which in the judgment of an investigator represents 
a SAE, may be reported on an expedited basis.
 
An investigator will communicate an initial SAE re
port within 24 hours of site awareness of 
occurrence to the IND sponsor by [CONTACT_33831]. 
 
A written report by [CONTACT_128176] 3 working 
days.  
In order for 
the
 
IND Sponsor to comply with regulations mandating sponsor notification of 
specified SAEs to the FDA within 7 and/or [ADDRESS_839666] submit 
additional information as soon as it is available.
 
5.4.
 
IND Sponsor Reporting to the FDA
 
The IND S
ponsor is responsible for making the determination of which SAEs are 
“serious and 
unexpected suspected 
adverse
 
reactions” (S[LOCATION_003]Rs) as defined in 21 CFR 312.32
.
 
•
 
Suspected adverse reaction
 
means any adverse event for which there is a reasonable 
possibility t
hat the drug caused the adverse event.
 
•
 
Unexpected Adverse Event
 
means an AE that is not listed in the 
IB
 
or is not listed at 
the specificity or severity that has been observed.  
 
All S[LOCATION_003]Rs (as determined by [CONTACT_9533]) will be reported to the FDA 
as IND Safety 
Reports; IND Safety Reports will also be provided to the IRB.
 
The IND Sponsor will also submit an IND Annual Report of the progress of the investigation to 
the FDA as defined in [ADDRESS_839667]
 
The f
ollowing information is consistent with NIH IRB Policy 801: Reporting Research Events, 
Version 1, effective July 1, 2019. 
 
Reportable Event 
-
 
An event that occurs during the course of human subject research that 
requires notification to the IRB.
 
For the pu
rposes of this policy, reportable events include the following:
 
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.0  
 
October 07
, 2022 
 
 
Page 
36
 
of 
73
 
 
•
 
Unanticipated Problems (UPs) involving risks to subjects or others, 
•
 
Non
-compliance (including major protocol deviations and noncompliance that is not 
related to a protocol deviation),
 
•
 
Deaths related or possibly related to research activities, and
 
•
 
New information that might affect the willingness of subjects to enroll or continue 
participation in the study.
 
5.5.1.
 
Unanticipated Problem (UP) Definition
 
An unanticipated problem (UP) is defined as any inc
ident, experience, or outcome that meets 
all 
of the following criteria:
 
•
 
Unexpected (in 
terms of 
nature, severity, or frequency
) given (a) 
the research 
procedures that are described in the protocol-
related documents, such as the IRB
- 
approved research protocol and informed consent document; and (b) 
the 
characteristics of the subject population being studied; 
and
 
•
 
Related 
or possibly related 
to participation in the research
 
(possibly related means 
there is a reasonable possibility that the incident, experience, or outcome may have 
been caused by [CONTACT_3459])
; 
and
 
•
 
Suggests that the research places subjects or others (which may include research staf
f, 
family members or other individuals not directly participating in the research) 
at a 
greater risk of harm (including physical, psychological, economic, or social harm) 
related to the research 
than was previously known or 
expected
. 
A UP must be reported within 7 calendar days of an investigator becoming aware of the actual or 
suspected UP
. 
5.5.2.
 
Non
-
Compliance Definition
 
Non
-
compliance is the failure of investigator(s) to follow the applicable laws, regulations, or 
institutional policies governing the protectio
n of human subjects in research, or the requirements 
or determinations of the IRB, whether intentional or not.   
Non
-compliance may be unintentional (e.g. due to lack of understanding, knowledge, or 
commitment), or intentional (e.g. due to deliberate choice to ignore or compromise the 
requirements of any applicable regulation, organizational policy, or determination of the IRB). 
Non
-
compliance is further characterized as serious or continuing as follows: 
 
•
 
Serious non
-compliance - 
Non
-
compliance, 
w
hether intentional or not, that results in harm 
or otherwise materially compromises the rights, welfare and/or safety of the subject. Non
-
compliance that materially 
a
ffects the scientific integrity or validity of t
he research may be 
considered serious non
-
compliance, even if it does not result in direct harm to research 
subjects.  
•
 
 
Continuing non
-
compliance
– A pattern of recurring non-
compliance that either has 
resulted, or, if continued, may result in harm to subjects or otherwise materially 
compromise the rights, welfare and/or safety of subjects, affect the scientific integrity of 
Product: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
37
 
of 
73
 
 
the study or validity of the results.  The pattern may comprise repetition of the same non
-
compliant action(s), or different noncomplia
nt events.  
 
Any actual or suspected non
-
compliance by [CONTACT_52624]/designee within [ADDRESS_839668] becomi
ng aware.
 
5.5.3.
 
Protocol Deviation Definition
 
A 
protocol d
eviation is defined as any change, divergence, or departure from the IRB
-
approved 
research 
protocol
 
and is further characterized as major and minor as follows:
 
•
 
Major Deviations 
–
 
Deviations from the IRB a
pproved protocol that have, or may 
have the potential to, negatively impact, the rights, welfare or safety of the subject, or 
to substantially negatively impact the scientific integrity or validity of the study. 
 
•
 
Minor Deviations 
–
 
Deviations that do not h
ave the potential to negatively impact the 
rights, safety, or welfare of subjects or others, or the scientific integrity or validity of 
the study.  
 
For the reporting purposes, failure of subjects to comply with the research protocol does not 
represent non
-
compliance unless that failure is due to an action or omission of a member of the 
research team, for example, the failure to give adequate instruction to the subject.
 
A major deviation must be reported within [ADDRESS_839669] the rights, safety, or welfare of participants or 
the study’s ability to produce scientifically valid results.  A series of minor d
eviations pointing 
toward a more global issue that could affect the rights, safety or welfare of the participant or 
affect the validity of the study should be reported as a major deviation.  In all other instances, a 
summary of minor deviations should be p
rovided to the IRB at the time of continuing review.
 
5.5.4.
 
Death
 
Any death of a research subject that is possibly, probably or definitely related to the research 
must be reported within [ADDRESS_839670]: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
[ADDRESS_839671] be reported within 
24 hours
.
 
The following will be reported within 
7 calendar days
 
of investigator awareness: 
 
•
 
Actual or suspected UPs;
 
•
 
Actual or suspected non
-
compliance;
 
•
 
Actual or suspected Major PDs;
 
•
 
S
AEs that are actual or suspected UPs;
 
•
 
New information that might affect the willingness of a subject to enroll or remain in 
the study;
 
Suspension or termination of research activities, including holds on new enrollment, placed upon 
the research by [CONTACT_43038]
y sponsor, NIH or IC leadership, or any regulatory agency. 
 
5.5.8.
 
Annual Reporting to the IRB
 
 
The following will be reported to the IRB in summary at the time of Continuing Review:
 
•
 
Summary of UPs and non
-
compliance;
 
•
 
AEs, including SAEs, that are not UPs, as a narrative summary statement indicating 
whether these events were within the expected range;
 
•
 
Minor PDs (aggregate summary);
 
Any trends or events which in the opi[INVESTIGATOR_629584]: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
[ADDRESS_839672]
ICAL CONSIDERATIONS
 
6.1.
 
Overview
 
This is a phase I dose
-
escalation study 
in healthy adults to assess 
the safety and 
pharmacokinetics of 
N6LS (VRC
-
HIVMAB091
-
00
-
AB), 
a human monoclonal antibody with 
broad HIV
-
[ADDRESS_839673] does not complete 
the minimum evaluations needed to meet the protocol 
criteria for the group dose safety or dos
e
-
escalation evaluation
. 
Dose escalation rules are described in 
Section
 
4.3
. 
 
6.1.1.
 
Treatment Assignments
 
The Adv
antage eClinical system (E
mmes
 
Corp, Rockville, MD) will be used to assign subjects 
to a 
dose 
group in active accrual at the time of enrollment.
 
If an enrolled 
subject
 
is discontinued 
from the study before he/she has received any study product, 
 
a
 
new eligible subject may be 
enrolled into the same group.  If a replacement is needed in the case of a subject withdrawal, the 
replacement subject will be assigned to the same treatment as the dropout subject in order to 
complete the safety dataset as pla
nned. 
 
6.2.
 
Sample Size Considerations
 
Although the study is primarily descriptive, 
the 
primary 
goal 
is 
to identify safety concerns 
associated with different N6LS dosages
 
in 
group sizes ranging from 3 to 5 subjects. 
For 
a group 
size of 3 subjects, there is a 90
% chance of observing at least 1 SAE if the true event rate is 
≥
 
0.536 and a 90% chance of observing no 
SAE
 
if the true 
event 
rate is 
≤
 
0.034. 
For 
a group size 
of 
5 subjects, 
there is a 90% chance of observing at least 
SAE 
if the true rate is 
≥ 
0.37 and a 
90% 
chance of observing no event if the true rate is 
≤ 
0.02.
 
The probabilities of observing 0 and 1 or 
more event 
are presented in 
Table
 
3
 
for a range o
f possible true event rates. 
These calculations 
provide a complete pi[INVESTIGATOR_629585]. For example, within the group of size n=3, if the true event rate is 
0.01, then t
here is a probability of 0.[ADDRESS_839674] 1 event; while, within the group of size n=5, if the true event rate is 0.01, then there is a 
probability of 0.951 to observe no event and a probability of 0.05
 
to observe more than 1 event
. 
 
Table
 
3
:
 
Event 
Probabilit
ies 
for
 
Different Scenarios
 
True 
Event Rate
 
Group Size
, 
N
=3
 
Group Size
, 
N
=5
 
Probability,
 
No Events Observed
 
Probability, 
 
≥ 1 Event Observed
 
Probability,
 
No Events Observed
 
Probability, 
 
≥ 1 Event Observed
 
0.[ADDRESS_839675]: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.0  
 
October 07
, 2022 
 
 
Page 
40
 
of 
73
 
 
Table
 4
 displays the upper and lower 95% exact binomial confidence bounds for all possible 
number of observed events in a group. For a group size of 3 subjects, the upper 95% exact 
confidence bound o
n the true rate is 0.708 if no events are observed; the lower bound will be 
0.292 if all subjects experience the event. Likewise, for a group size of 5 subjects, the upper 95% 
exact confidence bound of the true rate is 0.522 if no events are observed; the 
rate of the lower 
bound is 0.478 if all subjects experience the event.  
Table
 4: 
95% Confidence Intervals of the True Rate for All Possible Number of 
Observed Events within a Dose 
Group
 
Group Size
,
 
N=3
 
95% 
Confidence Interval
 
Group Size
,
 
N=5
 
95% Confidence Interval
 
Observed 
Rate
 
Lower 
Bound
 
Upper 
Bound
 
Observed 
Rate
 
Lower 
Bound
 
Upper Bound
0/3
 
0
 
0.708
 
0/5
 
0
 
0.522
 
1/3
 
0.008
 
0.906
 
1/5
 
0.005
 
0.716
 
2/3
 
0.094
 
0.992
 
2/5
 
0.053
 
0.853
 
3/3
 
0.292
 
1
 
3/5
 
0.147
 
0.947
 
 
 
 
4/5
 
0.284
 
0.995
 
5/[ADDRESS_839676] 95% 
confidence interva
ls 
will be 
summarized 
by [CONTACT_7169]. 
Summaries will also include the number 
and percentage of subjects 
with 
any solicited or unsolicited AE, overall and by [CONTACT_629618].  
Solicited Adverse Events
: 
Solicited 
AE
 
data 
will be 
collected after each 
produ
ct 
administ
ration.  
The number and 
percentage of subjects experiencing each type of solicited sign or symptom will be tabulated by 
[CONTACT_629619], select pooled groups (i.e., 
all 
IV 
dose groups, 
all 5
 mg/kg 
SC
 dose 
groups (no 
rHuPH20
), and 
all 
rHuPH20
 dose groups
),
 and overall (
all 
dose
 groups). 
Subjects 
with multiple occurrences of the same event will be counted once using the event of highest 
severity
.   
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.0  
 
October 07
, 2022 
 
 
Page 
41
 
of 
73
 
 
Adverse 
Events: 
All unsolicited AEs reported through 56-days post each product adminis
tration will be recorded 
and coded 
by [CONTACT_10607] (MedDRA) 
system organ class 
(SOC) 
and preferred term
 
(PT)
. The number and percentages of subjects with each unsolicited 
AE will be tabulated by [CONTACT_629620]
, by [CONTACT_7169]
, select 
pooled groups (i.e., 
all 
IV 
dose groups, all 5 mg/kg 
SC
 dose groups (no 
rHuPH20
), and 
all 
rHuPH20
 d
ose 
groups), and overall (all dose groups)
. Subjects with multiple occurrences of the 
same event will be counted once using the event highest severity or strongest relationship to the 
study treatment. 
A by-subject 
listing of 
all unsolicited AEs 
will provid
e details including severity, relationship to 
treatment type, 
seriousness, new medical condition status, onset
 
and end date
, duration, and 
outcome. 
Local laboratory values: 
Boxplots of local laboratory values will be generated for baseline values and for v
alues measured 
during the course of the study. Each boxplot will show the [ADDRESS_839677] 
[32]
. 
Since
 
VRC [ADDRESS_839678] 
coho
rt. 
  
6.3.5.
 
Pharmacokinetics Analysis
 
Blood samples for PK evaluations will be collected at time
-points defined in the Schedule of 
Evaluations (
Appendix I
).  
Individual Subject Pharmacokinetic Analysis
: A non-
compartmental PK analysis will be 
performed using Phoenix 7.0 (Certara
R
) or a similar program on the N6LS concentration data 
generated from each subject.
  Calculated PK parameters for IV Groups 1, 3, 4, and 6 
will 
include: area-under-the-curve (AUC), maximum concentration (C
max
), time to C
max
 
(T
max
), 
clearance (CL), volume of distribution (Vd
z
), terminal elimination rate constant (λ
z
) and the 
terminal half
-
life (T
1/2
).  For Groups 2, 5, 7 and 8, the PK para
meters will include AUC, C
max
, 
T
max
, apparent clearance (CL/F), apparent volume of distribution (Vd
z
/F), λ
z
 and T
1/2
.  C
max 
and 
T
max
 
will be taken directly from the observed concentration
-
time data.  The terminal slope, λ
z
, 
will be determined from the log
-linear portion of the curve and the T
1/2
 
calculated as 0.693/λ
z
.  
AUC will be determined using the linear trapezoidal method through the Week 24 PK sample for 
single dose groups (1-4, 7 and 8) and through Week 48 for multiple dose groups (5 and 6) or 
throu
gh the last PK sample with a concentration above the quantitative limit.  The AUC over the 
Product: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
[ADDRESS_839679] dose (AUC
0
-
WK12
) will be determined for all dose groups.  If the 
final sample (C
last
) has a measurable N6LS concentration, the rem
aining AUC after the final 
concentration (AUC
Clast
-
inf
) will be estimated as C
last
/λ
z
.  Data will be summarized by 
[CONTACT_629621], Vd and T
1/[ADDRESS_839680] 
doses.  The potential for non
-
linearity PKs among IV groups will be determined by [CONTACT_629622]
-
adjusted ratios for C
max 
and AUC
0
-
WK12
 
between IV groups.  Additional compartmental 
analysis will be performed as warranted by
 
[CONTACT_26739].
 
Population Pharmacokinetic Analyses:
  
Population PK analyses will be performed on the 
N6LS
 
PK data following IV and SC administration to determine compartmental PK parameters 
with the PK program NONMEM version 7.3 or later (ICON
R
).  Based on pri
or PK studies of 
bNAbs, a two compartment model will be used to analyze the N6LS PK data.  The population 
analysis will generate estimates for initial and final volumes of distribution (Vd
1
 
and Vd
2
), inter
-
compartmental clearance (Q), CL and bioavailabilit
y (F).  Individual 
subjects
’ empi[INVESTIGATOR_629586].  Given the 
small subject numbers, the population PK analysis will include a limited exploratory covariate 
analysis to assess dosing 
and clinical factors as fixed effects associated with N6LS PK 
parameters. The three factors that will be evaluated are dose level  (5 vs 20 vs 40 mg/kg) on CL 
Vd1, Vd2 and F;  repeat dosing CL Vd
1
, Vd
2
, and F; and EPD co
-
administration on SC F and 
absorpti
on rate.  
 
The longer compartmental half
-
life, T
1/2beta 
will be determined from CL,  Vd
[ADDRESS_839681] 5000 
replicates
.
 
6.3.6.
 
Interim Analyses
 
Preliminary PK analyses may be done once per dose level as the data for each dose level is 
obtained.  This may be performed before a dose group’s PK data is complete and may only 
generate a subset of the final PK parameters.  T
h
e 
interim analys
e
s will be used to inform 
decisions about the dose levels to be administered in 
future 
studies
 
with N6LS
. 
 
 
Product: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
43
 
of 
73
 
 
7.
 
PHARMACY PROCEDURES
 
The 
dose 
groups and 
N6LS 
dosing schedule are shown in
 
Table
 
1
.
 
Refer to
 
t
he 
N6LS 
IB
 
for 
further information about
 
N6LS
 
(VRC
-
HIVMAB091
-
00
-
AB)
 
administered in the absence
 
and 
presence
 
of
 
rHuPH20
.
 
7.1.
 
Study Produ
ct and Administration Regimen 
 
N6LS (VRC
-
HIVMAB091
-
00
-
AB) is a 
clear, 
colorless to yellow liquid
, 
sterile aqueous buffered 
solution
 
that is essentially free of visible particles and 
is 
filled into 10 mL single
-
dose vials.  
Each vial contains
 
a 
6.25 ± 0.10 mL volume 
of N6LS 
at a concentration of 100 ± 10 mg/mL in 
formulation buffer composed of 10 mM Sodium Citrate, 50 mM Sodium Chloride, 150 mM 
Arginine
-
HCl, and 0.002% Polysorbate
-
80 (PS
-
80) at pH 6.5. 
Vials have a nominal fill volume 
of 6.25 mL 
to enable withdrawal up to 6.0 mL.
 
In calculating the dose to administer and number of vials to thaw, it should be assumed that the 
concentration is 100 mg/mL and that a volume of at least [ADDRESS_839682] 
weighing 115 kg (the upper limit per protocol eligibility) who receives the 40 mg/kg dose, the 
N6
LS amount needed is calculated as follows: 115 kg x 40 mg/kg = 4600 mg of 
N6LS
, which 
corresp
onds to 46 mL of the 100 mg/mL solution. Since each product vial contains at least [ADDRESS_839683].
 
Preparation of 
N6LS 
for IV administration will require
 
a 100 mL bag 
of 
0.9% sodium chloride, 
United S
tates Pharmacopeia (
USP
)
 
(normal saline) and a weight
-
based amount of N6LS
,
 
as 
described in the IB
. Preparation of 
N6LS 
(with and without 
rHuPH20
) 
for 
SC administration will 
not require any diluent.
 
There are 
6
 
different schedules in the study described in
 
Appendix I
.
 
7.2.
 
N6LS 
(VRC
-
HIVMAB091
-
00
-
AB) 
Vialed 
Product
 
The N6LS product label designates the long
-
term storage temperature as 
-
35°C to 
-
15°C.  
Clinical site storage in a qualified, continuously monitored, 
temperature
-
controlled freezer with 
temperature excursions between 
-
45°C to 
-
10°C is acceptable.  
 
Following thaw, N6LS vials may be stored for up to 24 hours at 
15°C
 
to 
27°C and/or up to 4 
weeks at 2°C to 8°C.  Product may not be stored in direct sunlight
. If stored at 2
°C
 
to 
8°C, vials 
must be equilibrated 
to 15°C
 
to 
27°C for a minimum of [ADDRESS_839684]
 
 
EDP is supplied as 
a 
sterile solution at a concentrati
on of 1 mg/mL in 2 mL single
-
use glass vial 
containing 0.5 mg rHuPH20 (~110,000 U/mL). 
EDP
 
should be stored
 
as labeled, either at 
-
20°C 
± 5°C or 5°C ± 3°C
 
and 
protected from light. Vials of EDP for 
i
n
jection can be removed from 
frozen storage and 
placed in the refrigerator at 2
°
C to 8°C for thawing (1 to 2 hours)
, or 
room
 
temperature 
(20ºC to 25ºC) 
for 10 to 30 minutes
.
 
Once thawed, vials of EDP 
may be kept at 
room temperature 
(20ºC to 25ºC) 
for up to [ADDRESS_839685]: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
[ADDRESS_839686]
s
 
to the IND Sponsor. 
In the case of storage or 
shippi[INVESTIGATOR_007]/handling t
emperature excursions outside of the normal allowance for the storage device, 
the following procedure is to be followed:
 
1.
 
Quarantine the affected product in a separate area.  If the excursion results in thawed 
material, it must not be refrozen. Thawed vials
 
must be quarantined at 5°C ± 3°C. 
 
2.
 
Report the excursion to the IND sponsor’s authorized representative (SAR) or designee, 
any other parties required by [CONTACT_100412], and via email to 
[EMAIL_993]
.  
Do not use until the IND SAR or designee informs the 
site pharmacist whether continued clinical use of the product is acceptable.
 
3.
 
Inquiries sent to 
[EMAIL_993]
. will prompt an automatic email reply to 
the notifier that includes the Clinical Excursion Reporting Form (CERF) as an 
attachment.  
 
4.
 
Fill out the CERF as completely as possi
ble, either electronically or manually.  
 
5.
 
Email the completed form and relevant attachments (e.g., temperature charts) to 
[EMAIL_993]
, replying to the previous email.  
 
6.
 
After receipt and evaluation of the reported information, the Sponsor or manufacturer’s 
design
ee will notify the site pharmacist whether continued clinical use of the product is 
acceptable.
 
7.5.
 
Preparation of 
Study Product
(s)
 
(N6LS ± 
rHuPH20
)
 
for 
Administration 
 
This section describes how the site pharmacist will prepare the study product
s
 
for administ
ration 
and how the clinician will administer 
each 
product.  Clinician instructions on how to select an 
administration site are in 
Section
 
4.2.3
.  
 
N6
LS is a highly concentrated protein solution and may develop white, opaque to translucent 
particles after thawing. When particles are observed, they may disappear after a few hours at 
15°C
 
to 
27°C 
or storage at 2
o
C to 8
o
C. 
 
The following 
instructions apply to thawing N6LS:
 
1.
 
Thaw vial(s) for a minimum of 
90 minutes
 
at 
15°C
 
to 
27°C after removing from the freezer.  
(DO NOT move vials 
directly from the freezer to storage at 2°C to 8°C.)
 
2.
 
Keep the material at 
15°C
 
to 
27°C 
during the entire 
preparation period until use
, up to the 
maximum storage times described in 
Section
 
7.[ADDRESS_839687] the vials; if [ADDRESS_839688]: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
45
 
of 
73
 
 
b.
 
If 
more than 10 
particles are observed, return the vials to 2°C to 8°C storage. If the 
particles dissolve 
or if [ADDRESS_839689] be equilibrated at 
15°C
 
to 
[ADDRESS_839690] be used within 8 hours of any subsequent return to 
15°C
 
to 
[ADDRESS_839691] preparat
ion can be 
found in the IB.
 
7.5.1.
 
N6LS: Preparation for 
IV 
Administration
 
For each IV infusion order, the subject’s weight
, 
dose level
, and study group 
code will be 
included in the pharmacy order.  To prepare an IV infusion, 
the pharmacist will
: 1)
 
fill an empty 
sterile bag with 
100 mL of 
normal saline
 
or (if commercially available) obtain a pre
-
filled 100 
mL bag of normal saline
, 
2) 
calculate the total milligrams 
of N6LS 
needed
,
 
3)
 
retrieve the 
minimum number of thawed
 
vials 
required 
to prepare the
 
full dose
, 
4) 
withdraw
 
the necessary 
amount of N6LS, 
5)
 
add 
this volume 
to the sterile
 
bag 
using good pharmacy practices to 
maintain sterility
, and 6) immediately remove all air remaining in the bag
.
 
 
Prepared IV bags 
should contain [ADDRESS_839692]
 
comply 
with the following specifications: 1.2 micron PES (polyethersulfone) filter membrane, DEHP
-
free, latex
-
free (equi
valent to Braun #473994 filter extension set). When the in
-
line filter is 
added to the tubing, the administration set must then be primed. At the end of product 
administration, the 
IV 
administration set must be flushed with about 30 mL (or appropriate 
volu
me) of 
normal saline
. 
 
The study product solution will typi[INVESTIGATOR_629587]
 
[ADDRESS_839693] tolerance. The rate of 
infusion may range from 10
-
20 mg/kg/hr 
at
 
the lowest dose 
level
 
to 80
-
160 mg/kg/hr 
at
 
the highest dose 
level
.  The mL/hr infusion rate may vary based on 
the total volume needed to administer a full dose
.
 
An infusion time greater th
a
n 30 minutes is 
permitte
d.
 
7.5.2.
 
N6LS: Preparation for 
SC 
Administration 
 
For each SC administration order, the subject’s weight
, 
dose level
,
 
and
 
study group 
code will be 
included in the pharmacy order.  To prepare a SC administration dose, the pharmacist will 
calculate the total mg ne
eded and retrieve the minimum number of thawed 
N6LS 
vials needed to 
prepare the full dose.  Prior to preparation for administration, vials should be gently swirled for 
[ADDRESS_839694]: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
[ADDRESS_839695] be withdrawn from the vial into 1 to 4 syringes (BD Luer
-
Lok 
3 
mL syringe; REF # 309657) using a 5 micron filter needle (BD Blunt Fill Needle 
–
 
Filter , 18G 
1 ½ inch; REF# 305211). 
A new filter needle must be used for each syringe. The filter needle 
must be discarded prior to dispensing and replaced with a needle suit
able for SC injection at the 
time of administration.
 
The product may be administered by [CONTACT_269893]
.
 
The clinician 
will use proper SC technique to ensure administration into 
the 
SC fatty layer and a slow push to 
minimize dis
comfort or the excessive distention of overlying skin.
 
7.5.3.
 
N6LS with 
rHuPH20
: Preparation for SC Administration 
via Infusion Pump
 
For each SC administration order, the subject’s weight, dose level, and study group code will be 
included in the pharmacy order.  
To prepare a SC administration dose, the pharmacist will 
calculate the total mg of N6LS and units of 
rHuP
H
20 
needed
 
to achieve a 2000 U/mL 
concentration of rHuPH20, 
and retrieve the minimum number of thawed vials of N6LS 
and 
rHuP
H
20
 
needed to prepare the f
ull dose 
(inclusive of infusion tubing residual volume)
. Prior to 
preparation for administration, vials of N6LS should be gently swirled for 30 seconds. AVOID 
FOAMING and DO NOT SHAKE THE VIALS. If particles are observed, follow instructions in 
Section
 
7.5
. The vial
(s)
 
of EDP should be placed at room temperature 
(20°C to 25°C) 
for a 
minimum of
 
10 to
 
30 minutes (
but 
for not more than 
24
 
hours at 20°C to 25°C), and then gently 
swirled and inverted [ADDRESS_839696] be withdrawn from the N6LS vial using a 5 micron filter 
needle (e.g., BD Blunt Fill Needle 
–
 
Filter , 18G 
1 ½ inch; REF# 305211) an
d gently injected 
into a new vial/recipi[INVESTIGATOR_629588]. The 
required
 
volume of EDP must be withdrawn from 
the EDP vial using a BD 
Luer
-
Lok 1 mL syringe 
and gently injected into the vial/recipi[INVESTIGATOR_629589] N6LS. The combined N6LS and EDP solution sho
uld then be mixed thoroughly by 
[CONTACT_629623], 5 to 6 times (~10 seconds), while avoiding foaming. The mixed 
material can then be drawn into a sterile syringe
 
with size dependent on total fill volume
 
(
Note:
 
The prepared syringe should conta
in 
sufficient volume to accommodate the final dose volume, 
the priming volume, and the residual volume in the syringe after infusion
.
)
 
The product may be 
administered in a single site 
using an infusion pump and syringe (
i.e., 
Terumo Surflo
®
 
23G 
winged infu
sion set with B/Braun extension set 
[
product code ET06L
 
or equivalent
]
 
and 
Medfusion syringe pump
 
or equivalent
)
 
at a rate of 2
-
3
 
mL/min 
to ensure accurate and consistent 
administration. 
The clinician will use proper SC technique to ensure 
administration into SC fatty 
layer.
 
 
7.5.4.
 
Handling of Prepared 
Product 
for 
IV 
or SC
 
Administration
: N6LS and 
N6LS+
rHuPH20
 
After product preparation in
 
an
 
IV bag, the prepared N6LS may be stored 
at 
1
5
°C
 
to 
27°C for a 
maximum of [ADDRESS_839697] 
sunlight. 
 
After preparation in syringes for SC administration, the prepared N6LS may be stored 
at 2°C to 
8°C 
for 
up to 24 hours
,
 
followed by [CONTACT_629624] 
15
°C
 
to 
27°C
 
for
 
up to [ADDRESS_839698]: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
47
 
of 
73
 
 
Chemical and physical in
-
use stability data supports storage of N6LS mixed with EDP in 
syringes at 2°C
 
to 
8°C for up to 24 hours and
 
at
 
15
°C
 
to 
27°C
 
for up to [ADDRESS_839699]
s
 
will be individually labeled with the name [CONTACT_52659], volume, 
lot number, concentration, storage instructions, Investigational Use Statement (“Limited by 
[CONTACT_12201]”), and manufacturer information.
 
7.7.
 
Study
 
Product 
Accountabilit
y
 
The study pharmacist will be responsible for maintaining an accurate record of the
 
study group
 
codes, inventory, and an accountability record of 
all 
study 
products
.  Electronic documentation 
as well as paper copi[INVESTIGATOR_629590].
 
7.8.
 
Study Product Disposition
 
Empty vials
, including equipment used to prepare
 
the
 
N6LS and EDP mix
ture
,
 
and the unused 
portion of a vial will be discarded in a biohazard containment bag for incineration or 
decontamination by [CONTACT_629625]
.  Partially used vials will not be administered to othe
r subjects or used for 
in vitro
 
experimental studies. Any unopened vials that remain at the end of the study will be returned to 
the production facility or discarded at the discretion of the sponsor in accordance with policies 
that apply to investigational
 
agents.  
 
 
 
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.[ADDRESS_839700] PROTECTIONS AND ETHICAL 
OBLIGATIONS
 
This research study will be conducted in compliance with the protocol, Good Clinical Practices 
(GCP), and all applicable regulatory requirements.
 
8.1.
 
Informed Consent
 
The study informed consent (IC
F) is provided as a separate hard copy 
which
 
describes the 
investigational product to be used and all aspects involved in protocol participation.  
The PI [INVESTIGATOR_629591], methods, anticipated risks and benefits of the study before any 
protocol- 
specific procedures or study product is administered. The Assessment of 
Understanding (AoU) must be completed before the study ICF is signed. 
The acquisition of informed consent will be documented in the subject’s medical records, as 
required by [ADDRESS_839701].  
8.2.
 
Risk
/
Benefit
 
Assessment
  
8.2.1.
 
Potential Risks
 
Risks
 of N6LS and mAb 
Administration
 
Typi[INVESTIGATOR_897], 
the side effects of MAbs are mild but may include
 
reactions at injection site (pain, 
redness, bruising, swelling),
 
fever, chills, rigors, nausea, vomiting, pain, headache, dizziness, 
shortness of breath, bronchospasm, hypotension, hypertension, pruritus, rash, urticaria, 
angioedema, diarrhea, tachycardia
 or chest pain
. Up to G
rade 3 injection site erythema has been 
observed after N6LS+ rHuPH20 
injection, and some injection site reactions have 
lasted
 up to six 
weeks before completely resolving. 
Clinical use of MAbs that are targeted to cytokines or 
antigen
s associated with human cells may be associated with an increased risk of infections 
[33]
; 
however, this is not expected to be a risk for a MAb targeted to a viral antigen.
 
Administration of MAbs may cause immune reactions such as acute anaphylaxis, serum sickness 
and the generation of antibodies. Howeve
r, these reactions are rare and more often associated 
with MAb targeted to human proteins or with the use of murine monoclonal antibodies which 
would have a risk of human anti-mouse antibodies [33].  In this regard, as N6LS is expected to 
have a low risk of such side effects since it is directed 
against a viral antigen and 
is 
human
 in 
origin
.  
Published experience with 
other 
human MAb 
directed against the cell surface targets on 
lymphocytes have shown that infusion of a MAb may be associated with cytokine release, 
causing a reaction known as “cytokine release syndrome” (CRS) 
[34]. 
Most infusion
-
related 
events occur within the first 24 hours after beginning administration.  Severe  reactions, such as 
anaphylaxis, angioedema, bronchospasm, hypotension and hypoxia, are infrequent and more 
often associated with MAbs targeted to human proteins or when a non-human MAb, such as a 
murine MAb, is used 
[33]
.  Specifically, with regard to 
the rare 
CRS reactions, these 
generally  
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.[ADDRESS_839702] MAb 
treatment.  With licensed therapeutic MAbs, CRS is managed by [CONTACT_86964][INVESTIGATOR_629592], administration of histamine blockers and restarting the infusion at a slower rate 
[35]
.
 
Delayed allergic reactions to other MAbs may include a serum sickness type of reaction, which 
is characterized by [CONTACT_22815], fever, lymph node enlargement, and joint pains.  These symptoms 
may not appear until several days after the exposure to the MAb and is noted to be more 
common with chimeric types of MAbs [33]. 
There are several FDA
-
licensed MAbs for which reactions related to the rate of IV infusion have 
been described.  Some symptoms may be treated by [CONTACT_629626][INVESTIGATOR_51119]. Supportive 
treatment may also be indicated for some signs and symptoms.   
Participation in this study may limit a subject’s eligibility for other future MAb studies.
 
Risks of 
EDP
 Coadmini
stration
 
EDP 
coadministration may cause mild, tr
ansient injection site reactions, including erythema, 
pain, bruising, pruritus, burning, tenderness, edema, induration, irritation, paresthesia, numbness, 
and rash. Moderate injection site reactions have occurred less frequently and include burning, 
erythema, pain, and numbness. Mild-
to
-moderate headache is also commonly reported. Adverse 
events in clinical trials have otherwise reflected the adverse reaction profiles of the co
-
administered drug or have been associated with the rapid introduction of a relat
ively large 
volume of fluid in the SC space. 
Risks of Blood Drawing   
Blood drawing may cause pain and bruising and may, infrequently, cause a feeling of 
lightheadedness or fainting. Rarely, it may cause infection at the site where the blood is taken. In 
this study, an IV line that can be used for the collection of blood may 
be left in place for several 
hours on the days when there are frequent PK blood draws.  Problems from use of an IV for 
blood drawing are generally mild and may include pain, bruising, minor swelling or bleeding at 
the IV site and rarely, infection, vein irritation (called phlebitis), or blood clot. 
 
8.2.2.
 
Benefits
 
There are no direct benefits to study subjects from study participation. Others may benefit from 
knowledge gained in this study that may aid in the development of HIV 
risk
-reduction or 
therapeutic methods.
 
8.3.
 
Institutional Review Board
 
A copy of the protocol, informed consent form, other written subject information, and any 
advertising material will be submitted to the IRB for written approval.
 
The investigator must submit and, where necessary, obtain approval from the IRB for all 
subsequent protocol amendment
s and changes to the informed consent document. The 
investigator will notify the IRB of unanticipated problems, non-
compliance, deviations from the 
protocol, and serious AEs per IRB policy. 
Product: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
[ADDRESS_839703], exploratory laboratory evaluations related to vaccine or 
infectious disease r
esearch in general and for research assay validation.
 
 
Genetic testing may 
be performed
 
in accordance with
 
the genetic testing information that 
was 
included
 
in the study 
Informed Consent Form (
ICF
)
. 
 
Additional optional genetic testing, including transcrip
tome 
sequencing
 
may 
be done
 
on 
collected specimens 
in an effort to
 
assess the expression of genes involved in the immune 
response to vaccination. 
 
Results of genetic testing may have psychological implications for patients such as revelations 
regarding fut
ure health risks, incurable conditions, 
and/or
 
information contradictory to stated 
biological relationships. Genetics counseling and advice will be available from the NIH to help 
subjects at all study sites with the implications of findings, where appropri
ate. 
 
Following genetic testing, the data will be shared in a controlled
-
access public database for other 
investigators to benefit from it (e.g. the Database of Genotypes and Phenotypes dbGAP). 
However
 
no personal, identifiable information will be shared i
n this process as the results will 
only 
be shared
 
with a code.
 
Other optional analysis, including proteome, lipi[INVESTIGATOR_33771], metabolome, and exosome may be done 
on collected specimens to evaluate some proteins, lipi[INVESTIGATOR_805], metabolites, and low molecular weight 
molecu
les involved in the immune response to vaccination
.
 
Product: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
[ADDRESS_839704].  Samples 
are stored at the 
Vaccine Immunology 
Program laboratory 
(
Gaithersburg, MD
)
 
or VRC 
Laboratories in Building 40, which are both secure facilities with limited access.  Data will be 
kept in password
-
protected computers.  Only investigators or their designees will have access to 
the samples and d
ata.  Samples will be tracked in the Laboratory Information Management 
System (LIMS) database or using another software designed for this purpose (e.g., Freezerworks 
or GlobalTrace)
.
 
8.5.3.
 
Disposition of Samples, Specimens and Data at Completion of the Protocol 
 
In the future, other investigators (both at NIH and outside) may wish to study these samples 
and/or data.  IRB approval must be sought prior to any sharing of samples.  Any clinical 
information shared about those samples would similarly require prior IRB 
approval.  The 
research use of stored, unlinked or unidentified samples may be exempt from the need for 
prospective IRB review and approval.  Exemption requests will be submitted in writing to the 
NIH Office of Human Subjects Research, which is authorized 
to determine whether a research 
activity is exempt.
 
At the time of protocol termination, samples will remain in the V
IP
 
facility or VRC laboratories 
or, after IRB approval, transferred to another repository.  Regulatory oversight of the stored 
samples and 
data may be transferred to a stored samples protocol as part of the IRB
-
approved 
termination plan.  Data will be archived by [CONTACT_387716], or after IRB and study sponsor approval, it may be eithe
r destroyed 
or transferred to another repository.
 
8.5.4.
 
Loss or Destruction of Samples, Specimens or Data
 
Any loss or unanticipated destruction of samples (for example, due to freezer malfunction) or 
data (for example, misplacing a printout of data with identifi
ers) that compromises the scientific 
integrity of the study will be reported to the IRB in accordance with institutional policies.
 
The PI 
[INVESTIGATOR_125523].
 
8.6.
 
Subject Identification and Enrollme
nt of Study 
Subjects
 
All study activities will be carried out at the NIH CC. Study subjects will be recruited through 
on
-
site and off
-
site advertising done for the screening protocol, VRC 500 (NCT 01375530). 
Effort will be made to include women and minorit
ies in proportions similar to that of the 
community from which they are recruited and will be limited to persons at least [ADDRESS_839705]: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
52
 
of 
73
 
 
accompanied by [CONTACT_629627]
d draws combined will be $
430
; product administration 
visits without PK blood draws will be $3
75
.  The compensation will be $
200
 
for scheduled visits 
that include blood drawing, $
8
5 for clinic visits that do not include a blood draw or procedure, 
and $[ADDRESS_839706]: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
[ADDRESS_839707] be obtained for all amendments to the protocol and the 
informed consent document. 
Approval from Halozyme Therapeutics
, Inc.
 
may also be required, 
in 
accordance with 
any cooperative research
 
and development agreement (CRADA) or clinical 
trial agreement (CTA)
 
established for the study
.  
All study amendments will be submitted to the 
IRB for approval.
 
The IND Sponsor, 
NIH
 
IRB, Office of Human Research Protections, study PI, and FDA reserve 
the r
ight to terminate the study.  The PI [INVESTIGATOR_33773]’s completion 
or early termination.
 
9.2.
 
Study Documentation and Storage
 
The PI [INVESTIGATOR_629593], and 
a list of appropriately 
qualified persons to whom trial duties have been delegated
 
will be maintained
.
 
Source documents are original documents, data, and records from which the subject’s data are 
obtained.  These include but are not limited to hospi[INVESTIGATOR_1097], clinical and offic
e charts, 
laboratory and pharmacy records, microfiches, radiographs, and correspondence. Long
-
term 
storage of source documents may be in the form of electronic files. 
 
The PI [INVESTIGATOR_33774] a comprehensive and centralized filing 
system of 
all study
-
related (essential) documentation, suitable for inspection at any time by [CONTACT_178138], IRB, FDA, and/or applicable regulatory authorities. Elements include:
 
•
 
Subject files containing completed informed consent forms, and
 
supporting copi[INVESTIGATOR_33775] (if kept).
 
•
 
Study files containing the protocol with all amendments, IBs, copi[INVESTIGATOR_178107].
 
In addition, all original source documentation must be maintained and be readily avai
lable.
 
All essential documentation should be retained by [CONTACT_52644]. The FDA requires study records to be retained for up to 
two years after marketing approval or refusal (21 CFR 312.6
2).  No study document should be 
destroyed without prior written agreement between the VRC and the investigator.  Should the 
investigator wish to assign the study records to another party or move them to another location, 
they must notify the VRC in writin
g of the new responsible person and/or the new location.
 
9.3.
 
Clinical Monitoring, Data Collection and Data Sharing
 
9.3.1.
 
Clinical
 
Monitoring
 
Plan
 
The 
IND Sponsor or their authorized representatives are responsible for ensuring integrity of 
study data and compliance 
with the protocol. The PI [INVESTIGATOR_629594], the IRB and 
the FDA to inspect study documents (e.g., consent forms, drug distribution forms, and case 
Product: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
54
 
of 
73
 
 
report forms) and pertinent hospi[INVESTIGATOR_33778]. Site 
visits by [CONTACT_128186]: study operations, quality of data 
collected in the research records, the accuracy and timeliness of data entered in the database, and 
to determine that all process and regulatory requirements 
are met. Study monitoring visits will 
occur as defined by [CONTACT_180346]
.
 
9.3.2.
 
Data Collection
 
Clinical 
research data will be collected in a secure electronic web
-
based clinical data 
management system (CDMS) through a contract research organization, 
The 
E
mmes
 
Company 
LLC
 
(Rockville, MD).  Extracted
,
 
anonymized 
data will be sent to the PSRT for safety review 
and to Protocol Statistician for statistical analysis
.
 
9.3.3.
 
Source Documents
 
The site will maintain appropriate medical and research records for this trial, in compliance with 
 
International Conference on Harmonisation (
ICH
)
 
E6 
GCP, regulatory and institutional
 
requirements for the protection of confidentiality of subjects. Source data are all information, 
original records of clinical findings, observations, or other activities in a clinical trial necessary 
for the reconstruction and evaluation of the trial. Exa
mples of these original documents and data 
records include, but are not limited to, medical records, laboratory reports, pharmacy records and 
other research records maintained for the clinical trial. 
 
9.3.4.
 
Data Sharing
 
Data generated in this study will be share
d as de
-
identified data in the government
-
funded public 
repository, www.ClinicalTrials.gov.  
Data may be shared prior to publication at approved public 
presentations or for collaborative development and will be shared at the time of publication or 
within [ADDRESS_839708]: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.[ADDRESS_839709] sheet: 2017 statistics
. 2017; Available from: 
www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf
. 
2. Huang, J., et al., 
Identification of a CD4
-Binding-Site Antibody to HIV that Evolved 
Near
-Pan Neutralization Breadth.
 Immunity, 2016. 
45
(5): p. [ADDRESS_839710] and potent neutralization of HIV-1 by a gp41-specific human 
antibody.
 Nature, 2012. 
491
(7424): p. 406
-12. 
4. Wu, X., et al., 
Rational design of envelope identifies broadly neutralizing human 
monoclonal antibodies to HIV-1.
 Science, 2010. 
329
(5993): p. 856
-61. 
5. Kwon, Y., et al., 
Structure
-guided modification and optimization of antibody VRC07.
 
Retrovirology, 2012. 
9
(Suppl 2): p. O34. 
6. 
Mascola, J.R., et al., 
Protection of macaques against vaginal transmission of a 
pathogenic HIV
-1/SIV chimeric virus by [CONTACT_588627].
 
Nat 
Med, 2000. 
6
(2): p. 207-10. 
7. Pegu, A., et al., 
Neutralizing antibodies to HIV
-
[ADDRESS_839711] more effectively in 
vivo than those to the CD4 receptor.
 Sci Transl Med, 2014. 
6
(243): p. 243ra88. 
8. Rudicell, R.S., et al., 
Enhanced Potency of a Broadly Neutralizing HIV-
[ADDRESS_839712] Lentiviral Infection In Vivo.
 J Virol, 2014. 
88
(21): p. 
[ZIP_CODE]-82. 
9. Bar, K.J., et al., 
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment 
Interruption.
 N Engl J Med, 2016. 
375
(21): p. [ADDRESS_839713] and potent HIV 
antibodies that mimic CD4 binding.
 Science, 2011. 
333
(6049): p. 1633-7. 
11. Mouquet, H., et al., 
Complex-
type N
-glycan recognition by [CONTACT_100420].
 Proc Natl Acad Sci U S A, 2012. 
109
(47): p
. E3268-77. 
12. Walker, L.M., et al., 
Broad neutralization coverage of HIV by [CONTACT_305727].
 Nature, 2011. 
477
(7365): p. 466-70. 
13. Walker, L.M., et al., 
Broad and potent neutralizing antibodies from an African donor 
reveal a new HIV
-1 
vaccine target.
 Science, 2009. 
326
(5950): p. 285
-9. 
14. 
McLellan, J.S., et al., 
Structure of HIV
-1 gp120 V1/V2 domain with broadly neutralizing 
antibody PG9.
 Nature, 2011. 
480
(7377): p. 336-43. 
15. 
Doria
-Rose, N.A., et al., 
New Member of the 
V1V2
-
Directed CAP256
-VRC26 Lineage 
That Shows Increased Breadth and Exceptional Potency.
 J Virol, 2015. 
90
(1): p. 76-
91.
 
16. Kwon, Y.D., et al., 
Optimization of the Solubility of HIV-1-
Neutralizing Antibody 10E8 
through Somatic Variation and Structure-
Base
d Design.
 J Virol, 2016. 
17. Ko, S.Y., et al., 
Enhanced neonatal Fc receptor function improves protection against 
primate SHIV infection.
 Nature, 2014. 
514
(7524): p. 642-5. 
18. Gaudinski, M.R., et al., 
Safety and pharmacokinetics of the Fc-
modified HIV
-1 human 
monoclonal antibody VRC01LS: A Phase 1 open-
label clinical trial in healthy adults.
 
PLoS Med, 2018. 
15
(1): p. e1002493. 
19. Morrow, L., et al., 
Reduction in intrasubject variability in the pharmacokinetic response 
to insulin after subcutaneous co-administration with recombinant human hyaluronidase 
in healthy volunteers.
 Diabetes Technol Ther, 2011. 
13
(10): p. [ADDRESS_839714]: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.0  
 
October 07
, 2022 
 
 
Page 
56
 
of 
73
 
 
20. Morcos, P.N., et al., 
Pharmacokinetics and pharmacodynamics of single subcutaneous 
doses of tocilizumab administered with or without rHuPH20.
 
Int J Clin Pharmacol Ther, 
2013. 
51
(7): p. 537-48. 
21. Locke, K.W., D.C. Maneval, and M.J. LaBarre, 
ENHANZE((R)) drug delivery 
technology: a novel approach to subcutaneous administration using recombinant human 
hyaluronidase PH20.
 Drug Deliv, 2019. 
26
(1): p. 98-106. 
22. Ledgerwood, J.E., et al., 
Safety, pharmacokinetics and neutralization of the broadly 
neutralizing HIV
-1 human monoclonal antibody VRC01 in healthy adults.
 Clin Exp 
Immunol, 2015. 
23. Lynch, R.M., et al., 
Virologic effects of broadly neutralizing antibody VRC01 
administration during chronic HIV-
1 infection.
 Sci Transl Med, 2015. 
7
(319): p. 
319ra206. 
24. Shpi[INVESTIGATOR_83868], O. and C. Jackisch, 
Subcutaneous administration of rituximab (MabThera) 
and trastuzumab (Herceptin) using hyaluronidase.
 Br J Cancer, 2013. 
109
(6): p. 1556-61. 
25. Gaudinski, M.R., et al., 
Safety and pharmacokinetics of broadly neutralising human 
monoclonal antibody VRC07
-523LS in healthy adults: a phase 1 dose-
escalation clinical 
trial.
 Lancet HIV, 2019. 
26. 
FDA. 
Immunogenicity Testing of Therapeutic Protein Products —Developi[INVESTIGATOR_178110]-Drug Antibody Detection
. 2019; Available from: 
https://www.fda.gov/regulatory-
information/search
-fda-guidance-
documents/immunogenicity-
testing
-
therapeutic
-
protein
-products-developi[INVESTIGATOR_007]-and-
validating
-
assays
-
anti
-drug
. 
27. Li, M., et 
al., 
Human immunodeficiency virus type 1 env clones from acute and early 
subtype B infections for standardized assessments of vaccine
-
elicited neutralizing 
antibodies.
 J Virol, 2005. 
79
(16): p. [ZIP_CODE]-25. 
28. Allen, J.C. and H.G. Kunkel, 
Antibodies to genetic types of gamma globulin after 
multiple transfusions.
 Science, 1963. 
139
(3553): p. 418-9. 
29. Jefferis, R. and M.P. Lefranc, 
Human immunoglobulin allotypes: possible implications 
for immunogenicity.
 MAbs, 2009. 
1
(4): p. 332-
8.
 
30. Kickler, T.S., et al., 
The expression of IgG allotypes on platelets and immunization to IgG 
allotypes in multitransfused thrombocytopenic patients.
 Blood, 1990. 
76
(4): p. 849-52. 
31. Zalevsky, J., et al., 
Enhanced antibody half-
life improves in vivo activity.
 Nat Biotechnol, 
2010. 
28
(2): p. 157-9. 
32. 
FDA, 
Guidance for Industry: E9 Statistical Principles for Clinical Trials
. 1998, U. S. 
DHHS, FDA, CDER, CBER.
 
33. Hansel, T.T., et al., 
The safety and side effects of monoclonal antibodies.
 
Nature reviews. 
Drug discovery, 2010. 
9
(4
): p. 325-
38.
 
34. Bugelski, P.J., et al., 
Monoclonal antibody-induced cytokine-
release syndrome.
 Expert 
review of clinical immunology, 2009. 
5
(5): p. 499-521. 
35. Vogel, W.H., 
Infusion reactions: diagnosis, assessment, and management.
 Clin J Oncol 
Nurs, 2010. 
14
(2): p. E10-21. 
 
Product: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
57
 
of 
73
 
 
APPENDIX 
I
:
 
S
CHEDULE OF 
E
VALUATION
S
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.0  
 
October 07
, 2022 
 
 
Page 
58
 
of 
73
 
 
Schedule 1: 
IV 
Group 1 (5 mg/kg), 3 (20 mg/kg), and 4 (40 mg/kg)
  
 
Visit Number
 
01R
 
02
 
02A
 
02B
 
02C
 
02D
 
03
 
04
 
06
 
07
 
08
 
09
 
10
 
11
 
15
 
16
 
17
 
Time After Infusion
 
 
Pre
 
EOI
 
1hr
 
3h
 
6h
 
24hr
 
48hr
 
Wk1
 
Wk2
 
Wk3
 
Wk4
 
Wk8
 
Wk12
 
Wk16
 
Wk20
 
Wk24
 
1
Day of Study
 
-
42 to 
0
 
D0
 
D0
 
D0
 
D0
 
D0
 
D1
 
D2
 
D7
 
D14
 
D21
 
D28
 
D56
 
D84
 
D112
 
D140
 
D168
 
Clinical
 
Tube
^
 
Screen
 
Enroll
 
Day of 
A
dministration
 
 
 
 
 
 
 
 
 
 
 
 
VRC 500 Screening Consent
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VRC 60
9
 
AoU; Consent
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
Screen: Physical exam, ht, wt; Other: 
targeted exam, BP, pulse, temp; also wt at 
visit 02
 
 
X 
X 
X 
X 
 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Complete med history at screen; then 
interim med history
 
 
X 
X 
X 
 
 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
[ADDRESS_839715]
 
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CBC / differential
 
EDTA
 
[ADDRESS_839716],  ALP, creatinine
 
GLT
 
4
 
 
4
 
 
 
 
 
4
 
 
4
 
4
 
 
4
 
 
4
 
 
 
 
Total bili, BUN, albumin, protein, calcium, 
Na, K, Cl, CO
2
, glucose
 
(CMP)
 
GLT 
X 
 
X 
 
 
 
 
 
 
 
X 
 
 
 
X 
 
 
 
[ADDRESS_839717]: urine or serum
 
 
X
 
X
 
X
 
 
 
 
 
 
 
 
X
 
 
 
 
 
X
 
 
X
 
4
Pregnancy prevention counseling/ 
Reproductive Information Form
 
 
X 
X 
X 
 
 
 
 
 
 
 
X 
 
 
 
 
X 
 
X 
HIV 
Ab/Ag combo test
 
EDTA
 
[ADDRESS_839718]
 
8
 
8
 
8
 
 
 
 
 
 
8
 
8
 
8
 
8
 
8
 
8
 
8
 
8
 
8
 
8
 
Daily Volume (mL)
 
 
38
 
8
 
19
 
4
 
4
 
4
 
4
 
11
 
12
 
22
 
19
 
12
 
19
 
12
 
19
 
12
 
12
 
12
 
Cumulative 
Volume (mL)
 
 
38
 
46
 
65
 
69
 
7
3
 
7
7
 
8
1
 
9
2
 
10
4
 
12
6
 
14
5
 
15
7
 
17
6
 
1
88
 
20
7
 
2
19
 
23
1
 
24
3
 
Visit windows
:
 
Schedule visits 02A through [ADDRESS_839719] to day 0. 
Visit 02A
 
(+10 min)
; 
Visits 
02B and 02C 
(±
10 min); Visit 02D (
-
2 hrs
); 
Visits 03, 04 
(± 6 hrs); Visits 06, 
07, 08, 09 (±2 days), and Visits 10, 11, 15, 16 and 17 (±7 days).Visits 05, 12, 13 and 14 are not applicable to Schedule 1. 
1 
Day 0=day of first product administration.  Day [ADDRESS_839720] administration are the 
baseline for assessing subsequent AEs.  
 
2
 
Screening includes physical
 
exam with vital signs, height (ht) and weight (wt).  At other visits, if medically indicated, a targeted exam is performed. 
Otherwise only blood pressure (BP), pulse, and temperature are required, except at Visit [ADDRESS_839721], dosed based on “mg/kg”. 
Product: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
59
 
of 
73
 
 
3 
The PK blood draw “visits,” defined by [CONTACT_100424], are relative to the exact time of the end of infusion (EOI). 
 
The exact start and end times of 
product administration and the
 
time of PK blood draw(s) are recorded to ensure accurate PK analysis.  All subjects will be observed for 
[ADDRESS_839722] is given
. 
 
^
 
Tube types and 
blood 
volumes are shown to meet current institutional requirements and projected blood volumes. Different tubes for clinical evalua
tions 
may be used to
 
meet site requirements. 
Slig
h
tly d
ifferent volumes and tubes may be used for research blood samples when tubes as shown are not 
available
, o
r as otherwise instructed by [CONTACT_9533]
. Collected blood volumes will stay within the NIH CC blood draw limits
 
for each subject.
 
 
 
 
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.0  
 
October 07
, 2022 
 
 
Page 
60
 
of 
73
 
 
Schedule 2: 
SC 
Group 
2
 
(5 mg/kg)
 
Visit Number
 
01R
 
02
 
02A
 
03
 
04
 
05
 
06
 
07
 
08
 
09
 
10
 
11
 
15
 
16
 
17
 
Time After Infusion
 
 
Pre
 
EOI
 
24hr
 
48hr
 
72hr
 
Wk1
 
Wk2
 
Wk3
 
Wk4
 
Wk8
 
Wk12
 
Wk16
 
Wk20
 
Wk24
 
1
Day of Study
 
-
42 to 0
 
D0
 
D0
 
D1
 
D2
 
D3
 
D7
 
D14
 
D21
 
D28
 
D56
 
D84
 
D112
 
D140
 
D168
 
Clinical
 
Tube
^
 
Screen
 
Enroll
 
Day of
 
I
njection
 
 
 
 
 
 
 
 
 
 
 
 
 
VRC 500 Screening Consent
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VRC 609 AoU; Consent
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
Screen: Physical exam, ht, wt
; Other: 
targeted exam, BP, pulse, temp; also wt 
at visit 02
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Complete med history at screen; then 
interim med history
 
 
X 
X 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
[ADDRESS_839723]
 
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CBC / differential
 
EDTA
 
[ADDRESS_839724],  ALP, creatinine
 
GLT
 
4
 
 
4
 
 
4
 
 
 
4
 
4
 
 
4
 
 
4
 
 
 
 
Total bili, BUN, albumin, protein, calcium, 
Na, K, Cl, CO
2
, glucose
 
(CMP)
 
GLT 
X 
 
X 
 
 
 
 
 
X 
 
 
 
X 
 
 
 
[ADDRESS_839725]: urine or serum
 
 
X
 
X
 
X
 
 
 
 
 
 
X
 
 
 
 
 
X
 
 
X
 
4
Pregnancy prevention counseling/ 
Reproductive Information Form
 
 
X 
X 
X 
 
 
 
 
 
X 
 
 
 
 
X 
 
X 
HIV 
Ab/Ag combo test
 
EDTA
 
[ADDRESS_839726]
 
8
 
8
 
8
 
 
 
8
 
8
 
8
 
8
 
8
 
8
 
8
 
8
 
8
 
8
 
8
 
Daily Volume (mL)
 
 
38
 
8
 
19
 
0
 
11
 
12
 
12
 
22
 
19
 
12
 
19
 
12
 
19
 
12
 
12
 
12
 
C
umulative Volume (mL)
 
 
38
 
46
 
65
 
65
 
76
 
88
 
100
 
122
 
141
 
153
 
171
 
184
 
203
 
215
 
227
 
239
 
V
isit windows
:
 
Schedule visits 02A through [ADDRESS_839727] to day 0. 
Visit 02A 
(+
10 min); Visits 03, 04, 05 (± 6 hrs); Visits 06, 07, 08, 09 (
±
2 days); 
Visits 10, 11, 15, 16, 17 (±7 days). Visits 12-14 are not applicable to Schedule 2. 
1
 
Day 0=day of first product administration.  Day [ADDRESS_839728] 
administration are the baseline for assessing subsequent AEs.  
 
2
 
Screening includes physical exam with vital signs, height (ht) and weight (wt).  At other visits, if medically indicated, a t
argeted exam is performed.
 
Otherwise only blood pressure (BP), pulse, and temperature are required, except at Visit [ADDRESS_839729], dosed based on “mg/kg”. 
Product: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
61
 
of 
73
 
 
3 
The PK blood draw “visits,” defined by [CONTACT_629628], are relative to the exact time of the end of injection (EOI).  The exact start and end times 
of product administration and the time of PK blood draw(s) are recorded to ensure accurate PK analysis.  All subjects will be
 
observed for 
[ADDRESS_839730] is given
. 
 
^
 
Tube types and 
blood 
volumes are shown to mee
t current institutional requirements and projected blood volumes. Different tubes for clinical evaluations 
may be used to meet site requirements. 
Slightly different volumes and tubes may be used for research blood samples when tubes as shown are not 
availa
ble, o
r as otherwise instructed by [CONTACT_9533]
. 
Collected blood volumes will stay within the NIH CC blood draw limits for each subject.
 
 
 
 
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.0  
 
October 07
, 2022 
 
 
Page 
62
 
of 
73
 
 
Schedule 3: 
SC 
Group 
5
 
(5 mg/kg by [CONTACT_128174])
 
Visit Number
 
01R
 
02
 
02A
 
03
 
04
 
05
 
06
 
07
 
09
 
10
 
11
 
11A
 
11E
 
12
 
13
 
14
 
15
 
16
 
17
 
17A
 
17E
 
Time After Infusion
 
 
Pre
 
D0
 
EOI
 
D0
 
24hr
 
48h
r
 
72hr
 
1wk
 
Wk2
 
Wk4
 
Wk8
 
Pre
 
Wk12
 
EOI
 
Wk12
 
24hr
 
72hr
 
Wk13
 
Wk14
 
Wk16
 
Wk20
 
Pre
 
Wk24
 
EOI
 
Wk24
 
24hr
 
1
Day of Study
 
-
42 to 
 
0
 
D0
 
D0
 
D1
 
D2
 
D3
 
D7
 
D14
 
D28
 
D56
 
D84
 
D84
 
D85
 
D87
 
D91
 
D98
 
D112
 
D140
 
D168
 
D168
 
D169
 
Clinical
 
Tube
^
 
Screen
 
Enroll
 
Day of 
injection
 
 
 
 
 
 
 
 
Day of 
injection
 
 
 
 
 
 
 
Day of 
injection
 
 
VRC 500 Screening Consent
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VRC 60
9
 
AoU; Consent
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
Screen: Physical exam, ht, wt; Other: 
targeted exam, BP, pulse, temp; wt
 
at 
visits 02, 11, and 17
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
X 
X 
X 
X 
X 
X 
 
Complete med history at screen; then 
interim med hx
 
 
X 
X 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
 
 
[ADDRESS_839731]; clinic visit if indicated
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X
 
 
 
 
 
 
 
 
X
 
CBC / diff
 
EDTA
 
[ADDRESS_839732],  ALP, creatinine
 
GLT
 
4
 
 
4
 
 
4
 
 
 
4
 
4
 
 
4
 
4
 
 
 
4
 
4
 
4
 
 
4
 
4
 
 
 
Total bili, BUN, albumin, protein, calcium  
Na, K, Cl, CO
2
, 
glucose
 
(CMP)
 
GLT 
X 
 
X 
 
 
 
 
 
X 
 
 
X 
 
 
 
 
X 
 
 
X 
 
 
[ADDRESS_839733]: urine or serum
 
 
X
 
X
 
X
 
 
 
 
 
 
X
 
 
 
X
 
 
 
 
 
X
 
 
 
X
 
 
 
4
Pregnancy prevention counseling/ 
Reproductive Information Form
 
 
X 
X 
X 
 
 
 
 
 
X 
 
 
X 
 
 
 
 
X 
 
 
X
 
 
 
HIV 
Ab/Ag combo test
 
EDTA
 
[ADDRESS_839734]
 
8
 
8
 
8
 
 
 
8
 
8
 
8
 
8
 
8
 
8
 
8
 
 
 
 
8
 
8
 
8
 
8
 
8
 
 
 
Daily Volume (mL)
 
 
38
 
8
 
19
 
0
 
11
 
12
 
12
 
22
 
19
 
12
 
19
 
19
 
0
 
0
 
11
 
22
 
19
 
12
 
19
 
19
 
0
 
0
 
Cumulative Volume (mL)
 
 
38
 
46
 
65
 
65
 
76
 
89
 
100
 
122
 
141
 
153
 
172
 
191
 
191
 
191
 
202
 
224
 
243
 
255
 
273
 
293
 
293
 
293
 
Visit windows
:
 
Schedule visits 02A through [ADDRESS_839735] to visit 11. 
Visit A 
(+
10 min); Visit E 
(+ 1 day); Visits 03, 04, 05, 
and 
12 (± 6 hrs); Visits 06, 07, 13, and 14 (±2 days); Visits 09, 10, 11, 15, 16 and 17 (±7 days, with not less than 21 days 
between injections). Visits 08, 11B, 11C, 17B, and 17C are not applicable to Schedule 3. 
1
 
Day 0=day of first product administration. 
 
Day [ADDRESS_839736]: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
63
 
of 
73
 
 
2
 
Screening includes physical exam with vital signs, height (ht) and weight (wt).  At other visits, if medically indicated, a t
argeted exam is performed. 
Otherwise only blood pressure (BP) and temp
erature are required, except at Visits 02, 11, and [ADDRESS_839737], dosed based on “mg/kg”.
 
3 
The PK blood draw “visits,” defined by [CONTACT_100425], are relative to the exact time of the end o
f injection (EOI).  The exact start and end times 
of product administration and the time of PK blood draw(s) are recorded to ensure accurate PK analysis.  
S
ubjects will be observed for
 
[ADDRESS_839738] is 
given. 
 
*
The study schedule for subjects who disc
ontinue product administration will be modified
 
as follows: 
 
•
 
S
ubjects who have
 
only
 
received 
one 
product administration will follow Schedule 3 through Visit 10, and then move to Schedule 5. 
 
•
 
Subjects who have received 
two 
product administration
s 
will follo
w Schedule 3 through Visit 16 and then move to Schedule 5
.
 
^
 
Tube types and
 
blood
 
volumes are shown to meet current institutional requirements and projected blood volumes. Different tubes for clinical evalua
tions 
may be used to meet site requirements. 
Slig
htly different volumes and tubes may be used for research blood samples when tubes as shown are not 
available, o
r as otherwise instructed by [CONTACT_9533]
. 
Collected blood volumes will stay within the NIH CC blood draw limits for each subject.
 
 
 
 
 
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.0  
 
October 07
, 2022 
 
 
Page 
64
 
of 
73
 
 
Schedule 3 (continued): 
SC 
Group 5 (5 mg/kg by [CONTACT_128174])
 
Visit Number*
 
18
 
19
 
20
 
21
 
22
 
23
 
24
 
25
 
26
 
Time After Infusion
 
72hr
 
Wk25
 
Wk26
 
Wk28
 
Wk32
 
Wk36
 
Wk40
 
Wk44
 
Wk48
 
Day of Study
 
D171
 
D175
 
D182
 
D196
 
D224
 
D252
 
D280
 
D308
 
D336
 
Clinical
 
Tube
^
 
 
 
 
 
 
 
 
 
 
 
Targeted physical exam, BP, pulse, temp
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Complete med history at screen; then interim
 
med hx
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
CBC / diff
 
EDTA
 
[ADDRESS_839739],  ALP, creatinine
 
GLT
 
4
 
4
 
4
 
 
4
 
 
 
 
 
Total bili, BUN, albumin, protein, 
calcium, Na, K, Cl, 
CO
2,
 
glucose
 
(CMP)
 
GLT 
 
 
X 
 
 
 
 
 
 
[ADDRESS_839740]: urine or serum
 
 
 
 
X
 
 
 
X
 
 
 
X
 
1
Pregnancy prevention counseling / Reproductive 
Information Form
 
 
 
 
X 
 
 
X 
 
 
X 
HIV 
Ab/Ag combo test
 
EDTA
 
 
[ADDRESS_839741]
 
 
8
 
8
 
8
 
8
 
8
 
8
 
8
 
8
 
Daily Volume (mL)
 
 
11
 
22
 
19
 
12
 
19
 
12
 
12
 
12
 
12
 
Cumulative Volume (mL)
 
 
307
 
329
 
348
 
360
 
379
 
391
 
403
 
415
 
427
 
 
Visit windows
:
 
Schedule visits 17A through [ADDRESS_839742] to visit 17. 
Visit 
18 (± 6 hrs), Visits 19
-
22 (
±
2 days), and Visits 23
-26 (±
7 
days).  
[ADDRESS_839743] is given. 
*
The 
study schedule for subjects who discontinue product administration will be modified as follows: 
 
•
 
Subjects who have only received one product administration will follow Schedule 3 through Visit 10, and then move to Schedule
 
5. 
 
•
 
Subjects who have received tw
o product administrations will follow Schedule 3 through Visit 16 and then move to Schedule 5. 
^
 
Tube types and blood 
volumes are shown to meet current institutional requirements and projected blood volumes. Different tubes for clinical 
evaluations may be 
used to meet site requirements. 
Slightly different volumes and tubes may be used for research blood samples when tubes as 
shown are not available, o
r as otherwise instructed by [CONTACT_9533]. Collected blood volumes will stay within the NIH CC blood draw 
limits 
for each subject.
 
 
 
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.0  
 
October 07
, 2022 
 
 
Page 
65
 
of 
73
 
 
Schedule 4: 
IV 
Group 
6
 
(20 mg/kg by [CONTACT_128174])
 
Visit Number
 
01R
 
02
 
02A
 
02B
 
02C
 
02D
03
 
04
 
06
 
07
 
09
 
10
 
11
 
11A
 
11B
 
11E
 
12
 
13
 
14
 
15
 
16
 
17
 
17A
 
17B
 
Time After Day 0 Infusion
 
 
Pre
 
D0
 
EOI 
D0
 
1hr
 
3h
r
 
6h
r
 
24hr
 
48h
 
Wk1
 
Wk2
 
Wk4
 
Wk8
 
Pre
 
Wk
 
12
 
EOI
 
Wk
 
12
 
1hr
 
24hr
 
72hr
 
Wk13
 
Wk14
 
Wk16
 
Wk20
Pre
 
Wk24
EOI 
Wk24
1hr
 
1
Day of Study
 
-
42 to
 
0
 
D0
 
D0
 
D0
 
D0
 
D0
 
D1
 
D2
 
D7
 
D14
 
D28
 
D56
 
D84
 
D84
 
D84
 
D85
 
D87
 
D91
 
D98
 
D112
 
D140
 
D168
 
D168
 
D168
 
Clinical
 
Tube
^
 
Screen
Enroll
 
Day of
 
infusion
 
 
 
 
 
 
 
Day of 
infusion
 
 
 
 
 
 
 
Day of 
infusion
 
VRC 500 Screening Consent
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VRC 60
9
 
AoU; Consent
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
Screen: Physical exam, ht, wt; 
Other: targeted exam, BP, pulse, 
temp; also wt at visits 02, 11, 17
 
 
X 
X 
X 
X 
 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
 
Complete med history at screen; 
then interim med hx
 
 
X 
X 
X 
 
 
 
 
X 
X 
X 
X 
X 
X 
X 
 
 
 
X 
X 
X 
X 
X 
X 
 
 
[ADDRESS_839744];
 
clinic visit if 
indicated
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
CBC / diff
 
EDTA
[ADDRESS_839745],  ALP, creatinine
 
GLT
 
4
 
 
4
 
 
 
 
 
4
 
 
4
 
4
 
 
4
 
4
 
 
 
 
4
 
4
 
4
 
 
4
 
4
 
 
 
Total bili, BUN, albumin, protein, 
calcium, Na, K, Cl, CO
2,
 
glucose
 
(CMP)
 
GLT 
X 
 
X 
 
 
 
 
 
 
 
X 
 
 
X 
 
 
 
 
 
X 
 
 
X 
 
 
  
[ADDRESS_839746]: urine or serum
 
 
X
 
X
 
X
 
 
 
 
 
 
 
 
X
 
 
 
X
 
 
 
 
 
 
X
 
 
 
X
 
 
 
  
4
Pregnancy 
prevention counseling/        
Reproductive Information Form
 
 
X 
X 
X 
 
 
 
 
 
 
 
X 
 
 
X 
 
 
 
 
 
X 
 
 
X 
 
 
HIV 
Ab/Ag combo test
 
EDTA
 
[ADDRESS_839747]
 
8
 
8
 
8
 
 
 
 
 
 
8
 
8
 
8
 
8
 
8
 
8
 
 
 
 
 
8
 
8
 
8
 
8
 
8
 
 
 
Daily Volume (mL)
 
 
38
 
8
 
19
 
4
 
4
 
4
 
4
 
11
 
12
 
22
 
19
 
12
 
19
 
19
 
4
 
4
 
0
 
11
 
22
 
19
 
12
 
19
 
19
 
4
 
4
 
Cumulative Volume (mL)
 
 
38
 
46
 
65
 
69
 
73
 
77
 
81
 
92
 
104
 
126
 
145
 
157
 
176
 
195
 
199
 
203
 
203
 
214
 
236
 
255
 
267
 
286
 
305
 
309
 
313
 
Visit windows
:
 
Schedule visits 02A through [ADDRESS_839748] to Visit 11. 
Visits A
 
(+10 min); Visits
 
B 
and C 
(±
10 min); Visit 02D (
-
2 hrs); Visit E (+1 day); Visits 03, and 04 (±6 hrs); Visits 06, 07, 13, and 14 (
±
2 days); Visit 12 (+2 days), Visits 09, 10, 11, 15, 
16 and 17 (±7 days, with not less than 21 days between infusions). Visits [ADDRESS_839749]: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
66
 
of 
73
 
 
1
 
Day 0=d
ay of first product administration.  Day [ADDRESS_839750] administration are the baseline 
for assessing subsequent AEs.  
 
2
 
Screening includes physical exam with vital signs, height (ht) and weight (wt).  At other visits, if medically indicated, a t
argeted exam is performed. Otherwis
e 
only blood pressure (BP), pulse, and temperature are required, except at Visits 02, 11, and [ADDRESS_839751], dosed based on “mg/kg
.
”
 
3 
The PK blood draw “visits,” defined by [CONTACT_629629], are relative to the exact time of the end of infusion.  Exact start and end times of product 
administration and the time of PK blood draw(s) are recorded to ensure accurate PK analysis.  All subjects will be observed f
or 
[ADDRESS_839752] given. 
 
*
The 
study schedule for subjects who discontinue product administration will be modified as follows: 
 
•
 
Subjects who have only received one product administration will follow Schedule 
4
 
through Visit 10, and then move to Schedule 5. 
 
•
 
Subjects who have received two product administrations will follow Schedule 
4
 
through Visit 16 and then move to Schedule 5.
 
^
 
Tube types and
 
blood
 
volumes are shown to meet current institutional requirements and projected blood volumes. Different tubes for clinical evalua
tions 
may be used to meet site requirements. 
Slightly different volumes and tubes may be used for research blood samples when tube
s as shown are not 
available, o
r as otherwise instructed by [CONTACT_9533]
.
 
Collected blood volumes will stay within the NIH CC blood draw limits for each subject.
 
 
 
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.0  
 
October 07
, 2022 
 
 
Page 
67
 
of 
73
 
 
Schedule 4 (continued): 
IV 
Group 6 (20 mg/kg by [CONTACT_128174])
 
Visit Number*
 
17E
 
18
 
19
 
20
 
21
 
22
 
23
 
24
 
25
 
26
 
Time After Infusion
 
24hr
 
72hr
 
Wk25
 
Wk26
 
Wk28
 
Wk32
 
Wk36
 
Wk40
 
Wk44
 
Wk48
 
Day of Study
 
D169
 
D171
 
D175
 
D182
 
D196
 
D224
 
D252
 
D280
 
D308
 
D336
 
Clinical
 
Tube
^
 
 
 
 
 
 
 
 
 
 
 
Targeted physical exam, BP, pulse, temp
 
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Complete med history at screen; then interim med hx
 
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Phone contact; clinic visit if indicated
 
 
X
 
 
 
 
 
 
 
 
 
 
CBC / diff
 
EDTA
 
 
[ADDRESS_839753],  ALP, creatinine
 
GLT
 
 
4
 
4
 
4
 
 
4
 
 
 
 
 
Total bili, BUN, albumin, protein, calcium, Na, K, 
Cl, CO
2,
 
glucose
 
(CMP)
 
GLT 
 
 
 
X 
 
 
 
 
 
 
[ADDRESS_839754]: urine or serum
 
 
 
 
 
X
 
 
 
X
 
 
 
X
 
1
Pregnancy prevention counseling / Reproductive 
Information Form
 
 
 
 
 
X 
 
 
X 
 
 
X 
HIV 
Ab/Ag combo test
 
EDTA
 
 
 
[ADDRESS_839755]
 
 
 
8
 
8
 
8
 
8
 
8
 
8
 
8
 
8
 
Daily Volume (mL)
 
 
0
 
11
 
18
 
19
 
12
 
19
 
12
 
12
 
12
 
12
 
Cumulative Volume (mL)
 
 
316
 
327
 
345
 
364
 
376
 
395
 
407
 
419
 
431
 
443
 
 
Visit windows
:
 
Schedule visits 17A through [ADDRESS_839756] to visit 17. 
Visit E (+1 day); Visit 18 (+2 days), Visits 19
-
22 (
±
2 days), and Visits 23
-
26 (±7 days).
 
[ADDRESS_839757] is given.   
* 
The study schedule 
study schedule for subjects who discontinue product administration will be modified as follows:  
• Subjects who have only received one product administration will follow Schedule 4 through Visit 10, and then move to Schedule 5.  
• Subjects who have received two product administrations will follow Schedule 4 through Visit 16 and then move to Schedule 5. 
^
 
Tube types and blood 
volumes are shown to meet current institutional requirements and projected blood volumes. Different tubes for clinical 
evaluations may be used to meet site requirements
. Slightly different volumes and tubes may be used for research blood samples when tubes as 
shown are not available, o
r as otherwise instructed by [CONTACT_9533]. Collected blood volumes will stay within the NIH CC blood draw limits 
for each s
ubject.
 
Product: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
[ADDRESS_839758]: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.0  
 
October 07
, 2022 
 
 
Page 
69
 
of 
73
 
 
Schedule 5: For Subjects in Groups [ADDRESS_839759] Administration(s)
 
Visit Number
 
11
 
15
 
16
 
17
 
21 
22 
23 
Time After Infusion
 
Wk12
 
Wk16
 
Wk20
 
Wk24
 
Wk28
 
Wk32
 
Wk36
 
Day of Study
 
D84
 
D112
 
D140
 
D168
 
D196
 
D224
 
D252
 
Clinical
 
Tube
^
 
 
 
 
 
 
 
 
Targeted exam, BP, pulse, temp
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Interim med history
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Pregnancy test: urine or serum
 
 
 
X
 
 
X
 
 
 
X
 
Pregnancy prevention counseling/ Reproductive Information Form
 
 
 
X
 
 
X
 
 
 
X
 
Research Samples
 
 
 
 
 
 
 
 
 
PK 
samples
 
SST
 
[ADDRESS_839760]
 
8
 
8
 
8
 
8
 
8
 
8
 
8
 
Daily Volume (mL)
 
 
12
 
12
 
12
 
12
 
12
 
12
 
12
 
If starting at Visit 11
 
Cumulative Volume (mL), Group 5
 
 
184
 
196
 
2
08
 
22
0
 
 
 
 
Cumulative Volume (mL), Group 6
 
 
188
 
200
 
212
 
224
 
 
 
 
If starting at Visit 17
 
Cumulative Volume (mL), Group 5
 
 
 
 
 
285
 
297
 
309
 
321
 
Cumulative Volume (mL), Group 6
 
 
 
 
 
298
 
310
 
322
 
334
 
Visit windows
:
 ±[ADDRESS_839761] will continue study participation under this modified schedule
: 
  
•
 
If 
only one product administration 
was
 
received
, subjects will follow their originally assigned study schedule through Visit 10 and then move to 
Schedule 5 for Visits 11-17. T
he final study visit will be Visit 17 for these subjects.
 
•
 
If 
two 
product administration 
were 
received, subjects will follow their originally assigned study schedule through Visit 16 and then move to 
Schedule 5 for Visits 17-23
. The final study visit will be Visit 2
3 
for these subjects
. 
^
 
Tube types and blood 
volumes are shown to meet current institutional requirements and projected blood volumes. Different tubes for clinical 
evaluations may be used to meet site requirements
. Slightly different volumes and t
ubes may be used for research blood samples when tubes as 
shown are not available, o
r as otherwise instructed by [CONTACT_9533].  Collected blood volumes will stay within the NIH CC blood draw limits for 
each subject.
 
 
 
 
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 9.0  
 
October 07
, 2022 
 
 
Page 
70
 
of 
73
 
 
Schedule 6: N6LS + 
rHuPH20
 
SC Infusion Groups 7 (5 mg/kg) and 8 (20 mg/kg)
 
Visit Number
 
01R
 
02
 
02A
 
02B
 
03
 
04
 
05
 
06
 
07
 
08
 
09
 
10
 
11
 
15
 
16
 
17
 
Time After Infusion
 
 
Pre
 
EOI
 
4hr
 
24hr
 
48hr
 
72hr
 
Wk1
 
Wk2
 
Wk3
 
Wk4
 
Wk8
 
Wk12
 
Wk16
 
Wk20
 
Wk24
 
1
Day of Study
 
-
42 to 0
 
D0
 
D0
 
D0
 
D1
 
D2
 
D3
 
D7
 
D14
 
D21
 
D28
 
D56
 
D84
 
D112
 
D140
 
D168
 
Clinical
 
Tube
^
 
Screen
 
Enroll
 
Day of Administration
 
 
 
 
 
 
 
 
 
 
 
 
 
VRC 500 Screening Consent
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VRC 609 AoU; Consent
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
Screen: Physical exam, ht, wt
; Other: 
targeted exam, BP, pulse, temp; also wt 
at visit 02
 
 
X 
X 
X 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Complete med history at screen; then 
interim med history
 
 
X 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
[ADDRESS_839762]
 
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CBC / differential
 
EDTA
 
[ADDRESS_839763],  ALP, creatinine
 
GLT
 
4
 
 
4
 
 
 
4
 
 
 
4
 
4
 
 
4
 
 
4
 
 
 
 
Total bili, BUN, albumin, protein, calcium, 
Na, K, Cl, CO
2
, glucose
 
(CMP)
 
GLT 
X 
 
X 
 
 
 
 
 
 
X 
 
 
 
X 
 
 
 
[ADDRESS_839764]: urine or 
serum
 
 
X
 
X
 
X
 
 
 
 
 
 
 
X
 
 
 
 
 
X
 
 
X
 
4
Pregnancy prevention counseling/ 
Reproductive Information Form
 
 
X 
X 
X 
 
 
 
 
 
 
X 
 
 
 
 
X 
 
X 
HIV 
Ab/Ag combo test
 
EDTA
 
[ADDRESS_839765]
 
8
 
8
 
8
 
 
 
 
8
 
8
 
8
 
8
 
8
 
8
 
8
 
8
 
8
 
8
 
8
 
PBMC and Plasma
 
EDTA
 
20
 
 
10
 
 
 
 
 
 
 
 
 
10
 
10
 
 
 
 
 
Daily Volume (mL)
 
 
38
 
8
 
29
 
0
 
4
 
11
 
12
 
12
 
22
 
19
 
12
 
29
 
22
 
19
 
12
 
12
 
12
 
Cumulative Volume (mL)
 
 
38
 
46
 
75
 
75
 
79
 
90
 
1
0
2
 
1
1
4
 
1
3
6
 
1
5
5
 
1
6
7
 
196
 
21
8
 
2
37
 
2
49
 
2
61
 
2
73
 
Visit windows
:
 
Schedule visits 02A through [ADDRESS_839766] to day 0. Visit 02A (+10 min); Visit 02B (± 10 min); Visits 03, 04, 05 (± 6 hrs); Visits 06, 
07, 08, 09 (±2 days); Visits 10, 11, 15, 16, 17 (±7 days). Visits 12-14 are not applic
able to Schedule 
6. 
1
 
Day 0=day of first product administration.  Day [ADDRESS_839767] 
administration are the baseline for assessing subsequent AEs.  
 
2
 
Screen
ing includes physical exam with vital signs, height (ht) and weight (wt).  At other visits, if medically indicated, a targete
d exam is performed. 
Otherwise only blood pressure (BP), pulse, and temperature are required, except at Visit [ADDRESS_839768], dosed based on “mg/kg.” 
Product: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
71
 
of 
73
 
 
3 
The PK blood draw “visits,” defined by [CONTACT_629630]
, are relative to the exact time of the end of in
fusion
 
(EOI).  The exact start and end times 
of product a
dministration and the time of PK blood draw(s) are recorded to ensure accurate PK analysis.  All subjects will be observed fo
r [ADDRESS_839769] is given. 
 
^
 
Tube types and
 
blood
 
volumes are shown to meet current institutional requirements and projected blood volumes. Different tubes for clinical 
evaluations may b
e used to meet site requirements. 
Slightly different volumes and tubes may be used for research blood samples when tubes as shown 
are not available, o
r as otherwise instructed by [CONTACT_9533]
.
 
Collected blood volumes will stay within the NIH CC blood dr
aw limits for each 
subject.
 
 
 
 
 
 
 
Product: VRC
-
HIVMAB091
-
00
-
AB (N6LS)
 
 
Protocol VRC 609, Version 
9
.0
 
 
 
October 07
, 2022
 
 
 
Page 
72
 
of 
73
 
 
APPENDIX 
II
:
 
A
SSESSMENT OF 
R
ELATIONSHIP TO 
S
TUDY 
P
RODUCT AND 
T
ABLE 
F
OR 
G
RADING 
S
EVERITY 
O
F 
A
DVERSE 
E
VENTS
Product: VRC
-
HIVMAB091
-00-
AB (N6LS)
  
Protocol VRC 609, Version 7.[ADDRESS_839770]
: 
 
The relationship between an adverse event (AE) and the product will be assessed by [CONTACT_178140]. 
 
•
 
Definitely Related
. The AE and administration of study product are related in time, and a 
direct association can be demonstrated. 
 
•
 
Probably Related
. The AE and administration of study product are reasonably related in 
time, and the AE is more likely explained by [CONTACT_178141].  
•
 
Possibly 
Related
. The AE and administration of study product are reasonably related in 
time, but the AE can be explained equally well by [CONTACT_178142].  
•
 
Not Related
. There is not a reasonable possibility that the AE is related to the study 
product.  
For purposes of preparing data reports in which AE attributions are limited to “
Related
” or “
Not 
Related
”, in this protocol, the “Definitely, Probably and Possibly” attributions will be mapped to 
the “Related” category. The definitions that apply when these two categories alone are used are 
as follows: 
 
•
 
Related
 – There is a reasonable possibility that the AE may be related to the study 
product.  
•
 
Not Related
 – 
There is not a reasonable possibility that the AE is related to the study 
product. 
Table for Grading Severity of Adverse Events
: 
For consistency with other studies of VRC MAb products, the U.S. Department of Health and 
Human Services, National Institutes of Health, National Institute of Allergy and Infectious 
Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult 
and Pediatric Adverse Events, Corrected Version 2.1. [July 2017]. Available from: 
https://rsc.tech
-
res.com/docs/default
-
source/safety/division
-
of
-
aids
-
(daids)
-
table
-for-grading-the-
severity
-
of
-adult-and-
pediatric
-adverse-
events
-
corrected
-v-2-1.pdf. 
The Table will be used as posted at the link above with the following exemptions: 
•
 
Weight 
loss will be recorded as an adverse event only if it is considered deleterious to 
the participant’s health.
 
•
 
For severity grading of the solicited bruising parameter at the product administration 
site, the definitions based on size of the largest diameter and listed for the “Injection 
Site Erythema or Redness” will be used.
 
The severity grade definition for “Bruising” 
provided under the Dermatologic Clinical Conditions will be used only for 
unsolicited adverse events involving bruising at other body location
s.  
•
 
Creatinine changes will be graded on the basis of the upper limit of normal provided 
by [CONTACT_52656]. 
•
 
Creatinine clearance changes will be graded according to m
L/min provided by [CONTACT_629631] b
aseline.
 
Subclinical CMP results for sodium, potassium, chloride, bicarbonate, BUN, and 
glucose will not be considered an AE unless grade 2 or greater. 
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 10/07/[ADDRESS_839771]
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
PRINCIPAL INVESTIGATOR:  
[INVESTIGATOR_100364], MD
STUDY TITLE: 
VRC 609 (18I0105): A Phase I, Open-Label, Dose-Escalation Study of the 
Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB 
(N6LS), Administered Intravenously or Subcutaneously with or without Recombinant Human 
Hyaluronidase PH20 (rHuPH20) to Healthy Adults
STUDY SITE: 
NIH Clinical Center
Cohort: Healthy Volunteer
Consent Version:  October 07, 2022, Version 9.[ADDRESS_839772] ABOUT THIS STUDY? 
Principal Investigator: [INVESTIGATOR_100364], MD.,
Study Coordinator:
KEY INFORMATION ABOUT THIS RESEARCH 
This consent form describes a research study and is designed to help you decide if you would 
like to be a part of the research study.  
You are being asked to take part in a research study at the National Institutes of Health (NIH). 
This section provides the information we believe is most helpful and important to you in making 
your decision about participating in this study. Additional information that may help you decide 
can be found in other sections of the document. Taking part in research at the NIH is your choice.
This is a study of an experimental drug called N6LS. N6LS is a monoclonal antibody (mAb) 
that targets HIV. The main purpose of this study is to evaluate if N6LS is safe and how your 
body responds to it. Since this is the first time N6LS will be given to people, we do not know 
how your body will respond. We also want to check if your body will recognize N6LS and make 
an immune response to it. You cannot get HIV from N6LS. 
About [ADDRESS_839773] completed the study. If you decide to take part, you will be enrolled in 
Groups 7 or 8 and you will be in the study for about 24 weeks (6 months) and get N6LS one 
time on Day 0 as an injection in the fat under your skin, subcutaneously (SC). N6LS will be 
mixed with rHuPH20. rHuPH20 helps to increase the distribution of injected drugs. 
If you have side effects from N6LS, we expect them to like the side effects that occur with 
similar mAbs. These side effects usually occur within the first [ADDRESS_839774] blood samples from you. Some of your blood will be stored
            1  010 
                   10/31/2022
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 10/07/[ADDRESS_839775] the 
study, please inform your study team to ensure a safe withdrawal from the research.  
WHY IS THIS STUDY BEING DONE?
HIV infection is a serious disease with no cure or vaccine to prevent it. Researchers have been 
working hard to figure out new ways to treat or prevent HIV infection. Using antibodies is one 
way to prevent HIV infection that seems promising. Antibodies are naturally made by [CONTACT_100427].  This study will test an antibody called N6LS. 
N6LS has been used in the lab to block an HIV-like virus from causing infection in animals. The 
U.S. Food and Drug Administration (FDA) only allows it to be used for research because it is an 
experimental product.  The study will also test N6LS mixed with an enzyme, rHuPH20
 
(recombinant human hyaluronidase PH20). rHuPH20 increases the spread of fluids injected 
underneath your skin (subcutaneously, SC) and allows for the rapid delivery of large volume 
injections that can be given with a single needle. 
This study is the first time N6LS is tested in humans. N6LS is given into a vein in your arm 
(intravenously, IV) or as an injection underneath your skin subcutaneously. This study will be 
the first to test N6LS mixed with rHuPH20 in Groups 7 and 8. This study uses the same strength 
of enzyme that is given to patients receiving FDA approved products like trastuzumab and 
rituximab, used to treat cancer; and HyQvia
®
, used to treat immune problems in people with low 
antibody levels.
The goals of this study are:  

To see if N6LS alone and N6LS mixed with rHuPH20 is safe and well-tolerated.  

To measure the amount of N6LS that can be found in your body after you get it and how 
the levels of N6LS change over time.

To check if your body will recognize N6LS and make a response to it. 
            1  010 
                   10/31/2022
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 10/07/[ADDRESS_839776](S)
The N6LS antibody is a monoclonal antibody (MAb) that targets HIV. Monoclonal means that all 
the N6LS antibodies are exactly the same and have been made artificially in the lab. The part of 
N6LS that binds to HIV was first discovered in a person who had HIV and controlled the infection 
for more than [ADDRESS_839777] 
there is more space underneath your skin for larger amounts of N6LS to enter more easily. Once 
rHuPH20 is gone, your body builds the hyaluronan back up. The changes caused by [CONTACT_350767]20 are 
gone within 24-48 hours after it is given. 
WHAT WILL HAPPEN DURING THE STUDY?
The study will have [ADDRESS_839778] people will get N6LS into a vein (IV).  Some people will get N6LS with or 
without rHuPH20 into the belly fat under the skin (SC). You will be in the clinic for about 8 hours 
on the day(s) N6LS is given.  Other clinic visits will take about [ADDRESS_839779] 
of N6LS mixed with rHuPH20 given in one SC injection. This information will be helpful for 
future uses of N6LS and rHuPH20. 
Enrollment in Groups 1-6 is complete. If you agree to take part in this study, you will be enrolled 
in Group 7 or Group 8 and get 1 dose of N6LS + rHuPH20.  You will be weighed on the day N6LS 
is to be given. Your body weight is used to calculate the amount of N6LS you will get.  
The dose groups are shown in the Study Design table. 
            1  010 
                   10/31/2022
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 10/07/[ADDRESS_839780] be negative in order to get N6LS. 

IV Dosing Groups (1, 3, 4, and 6): 
If you are assigned to Groups 1, 3, 4, or 6, a thin tube will be placed in your arm vein on 
the day you are to get the study product.  We will place a second IV line in a vein on your 
other arm for blood sample collection. The N6LS will be given directly into your vein using 
a pump to control how fast it goes in.  The goal is to give the N6LS in about [ADDRESS_839781] blood samples from you before and after each infusion. You will also be asked 
to come back to the clinic 4-5 times between and after these doses.
Study Design
Study Products
Dosing Schedule
Dose
Groups
Participants
N6LS Dose
rHuPH20
Dosing Site
Day 0
Week 12
Week 24
Total Number 
of Study Visits
1
3
5 mg/kg  
-
IV
X
13
2
3
5 mg/kg  
-
SC
X
14
3
3
20 mg/kg  
-
IV
X
13
4
3
40 mg/kg  
-
IV
X
13
5
5
5 mg/kg  
-
SC
X
X
X
25
6
5
20 mg/kg  
-
IV
X
X
X
24
7
5
5 mg/kg  
+
SC
X
14
8
5
20 mg/kg  
+
SC
X
14
Total
32
IV= using an arm vein; SC = under skin
Note: The dose of rHuPH20 is 2000 units per mL relative to the N6LS dose 
volume.
            1  010 
                   10/31/2022
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 10/07/[ADDRESS_839782]
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY

SC Dosing Groups (2 and 5):
If you are assigned to Groups [ADDRESS_839783] blood samples from you before the injection and then at 
every scheduled follow-up visit.  

SC Dosing Groups with rHuPH20 (7 and 8):
If you are assigned to Groups [ADDRESS_839784](s).  You will need to record your highest temperature 
and any symptoms you have. You will use the measuring tool to measure any redness, swelling, 
or bruising you may have at the injection site. You will get a password to a secure website to record 
this information. If you do not have a computer, you may use a paper diary instead.  
You should tell a VRC nurse or doctor as soon as possible if you have any side effects after you 
get the study product(s).  You can reach the staff by [CONTACT_648] [ADDRESS_839785] symptoms, you may need to come into the clinic for a physical exam before your next 
scheduled visit.  It is very important that you follow the instructions from the clinic staff. 
Follow-up visits:
  We will check you for any health changes or problems at each visit.  We will 
ask you how you are feeling and if you have taken any medications.  We will draw about [ADDRESS_839786] you for HIV. We will tell you how to remain HIV-uninfected and give you prevention 
resources. If you are infected with HIV, you will not be able to receive N6LS. We will tell you 
            1  010 
                   10/31/2022
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 10/07/[ADDRESS_839787] questions about HIV testing, you should discuss them with the study nurse or doctor. 
You may also call an NIH Clinical Center HIV counselor at [PHONE_2330].
MONITORING OF THE STUDY
A group of physicians and scientists at NIH will monitor safety in this study. This group will 
review the information from the study and will pay close attention to possible harmful reactions.  
If serious side effects occur, further dosing with the study product(s) may be delayed or canceled.
GENETIC TESTING
Some of the blood drawn from you as part of this study will be used for genetic tests. Some genetic 
tests are done in research studies to see if genetic differences in people cause different types of 
immune responses.  Your blood sample used in these genetic tests will not have your name [CONTACT_629633].  These tests are not used to check your health 
and we will not tell you the results. 
The genetic testing performed in this study is for research purposes only. Any genetic information 
collected or learned about you will be kept confidential.
HOW MANY PEOPLE WILL PARTICIPATE IN THIS STUDY?
Thirty-two (32) to 40 people will take part in this study at the NIH Clinical Center in Bethesda, 
Maryland.
WHAT ARE THE RISKS AND DISCOMFORTS OF BEING IN THE STUDY?
Risks of N6LS: This study is the first time N6LS is given to people. As of August 4, 2021, N6LS 
has been given to [ADDRESS_839788].  Slowing or 
stoppi[INVESTIGATOR_100386].   
Side effects to N6LS-like antibodies given by [CONTACT_629632]/tenderness, itchiness, 
redness and/or swelling at the site of injection. Two people in the trial who received N6LS 
+rHuPH20 SC developed larger injection site redness. The redness was almost [ADDRESS_839789] other signs or symptoms such as 
fever, scarring, or any other skin related issues. The team determined it was safe to continue 
            1  010 
                   10/31/2022
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 10/07/[ADDRESS_839790] is 
given. This reaction can include difficulty breathing, low blood pressure, hives, rash, or swelling 
in the mouth and face. 
Serum sickness is a type of reaction that may happen several days or weeks after an antibody is 
given.  This reaction may include hives, rash, fever, enlarged lymph nodes, muscle pains, or joint 
pains.  
Some antibodies of the type that change how the immune system works can increase the risk of 
serious infections.  N6LS is not expected to increase the risk of serious infections because it attacks 
a virus and does not target the human immune system.
Unknown risks: N6LS may have other side effects that are not yet known. Participation in this 
study may affect your eligibility for future monoclonal antibody studies. We will give you any 
new information about risks or other information that may affect your decision to continue in the 
study as it becomes available.
You may not donate blood while taking part in this study and you may not donate blood for one 
year after the date of your last dose of N6LS. 
Risks of rHuPH20: This study is the first time that a combination of N6LS and rHuPH20 will be 
given to people. The active ingredient in rHuPH20 (hyaluronidase) has been given to roughly 
1,[ADDRESS_839791] experienced mild to moderate headache. 
Risks of IV or SC dosing:  General risks of methods that use a needle include stinging, discomfort, 
pain, soreness, redness, bruising, swelling or a tiny cut at the needle insertion site.
Risks of Blood Drawing: Blood drawing may cause pain, bruising, and may cause a feeling of 
lightheadedness or fainting.  Rarely, it may cause infection at the site where the blood is taken. An 
IV line may be placed in your vein for a few hours on a day N6LS is given by [CONTACT_24636].  Problems at the 
IV site are usually mild and may include pain, bruising, minor swelling, or bleeding.  Rarely, there 
may be an infection, vein irritation, nerve problem, or blood clot.  
What are the risks related to pregnancy? 
If you are able to become pregnant, we will ask you to have a pregnancy test before starting this 
study. You must use effective birth control methods and try not to become pregnant while 
participating in this study. If you become pregnant, there may be unknown risks to the fetus or 
            1  010 
                   10/31/2022
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 10/07/[ADDRESS_839792] any more blood for research.  However, you will be asked to continue with study follow-
up visits to check on your health and to report the outcome of the pregnancy. If you plan to become 
pregnant in the future, please discuss with the study team how long you need to wait before 
becoming pregnant after completing the study.
WHAT ARE THE BENEFITS OF BEING IN THE STUDY?
You will not benefit from being in this study.
Are there any potential benefits to others that might result from the study?
Others may benefit in the future from the information that will be learned from the study
WHAT OTHER OPTIONS ARE THERE FOR YOU?
Instead of being in this study, you could choose not to take part. You may be eligible 
for other VRC studies.
 
DISCUSSION OF FINDINGS
New information about the study
If we find out any new information that may affect your choice to participate in this study, we 
will get in touch with you to explain what we have learned. This may be information we have 
learned while doing this study here at the NIH or information we have learned from other 
scientists doing similar research in other places.
Return of research results
At each visit you will be checked for any health changes or problems. Blood will be drawn at 
almost every study visit to check on your health. You will be told right away, either by [CONTACT_100430] a health problem.
The results of this study may be reported in medical journals, on the internet or at scientific 
meetings. We will give you information about how to find the study results once they are available.
EARLY WITHDRAWAL FROM THE STUDY 
You may be removed from the research study by [CONTACT_100431]:

You don't keep appointments or follow study procedures;

You get a serious illness that needs ongoing medical care;

You become pregnant;

You need to get treatment with a medication that affects your immune system 
(such as a steroid like prednisone);
            1  010 
                   10/31/2022
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 10/07/[ADDRESS_839793]
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY

If the researcher believes that it is in your best interest to remove you from the study;

The study is stopped by [CONTACT_17513], the study sponsor or study 
investigators. If   this happens, we will tell you why.
If you agree to take part in this study, it is important for you to keep all of your appointments. Your              
participation in this study is completely voluntary. You can choose to stop taking part in the study 
at any time. There is no penalty or loss of benefits if you choose to leave the study.
STORAGE, SHARING AND FUTURE RESEARCH USING YOUR SPECIMENS AND 
DATA
Will your specimens or data be saved for use in other research studies? As part of this study, we 
are obtaining specimens and data from you. We will remove all the identifiers, such as your 
name, date of birth, address, or medical record number and label your specimens and data with 
a code so that you cannot easily be identified. However, the code will be linked through a key to 
information that can identify you. We plan to store and use these specimens and data for studies 
other than the ones described in this consent form that are going on right now, as well as studies 
that may be conducted in the future. These studies may provide additional information that will 
be helpful in understanding other diseases or conditions. This could include studies to develop 
other research tests, treatments, drugs, or devices, that may lead to the development of a 
commercial product by [CONTACT_100432]/or its research or commercial partners. There are no plans 
to provide financial compensation to you if this happens. Also, it is unlikely that we will learn 
anything from these studies that may directly benefit you.
By [CONTACT_100433], you give permission for your coded specimens and data to 
be stored and used for future research as described above.
Will your specimens or data be shared for use in other research studies?
We may share your coded specimens and data with other researchers.  If we do, while we will 
maintain the code key, we will not share it, so the other researchers will not be able to identify 
you.  They may be doing research in areas that are similar to this study or in other unrelated 
areas. These researchers may be at NIH, other research centers and institutions, or commercial 
entities.
By [CONTACT_100433], you give permission for your coded specimens and data to 
be shared with other researchers and used by [CONTACT_100435]. 
If you change your mind and do not want us to use your specimens and data for future research, 
you should contact [CONTACT_100434]. We will do 
our best to comply with your request but cannot guarantee it. For example, if research with your 
specimens and/or data has already been completed, the information from that research may still 
be used. Also, for example, if the specimens and data have been shared already with other 
researchers, it might not be possible to withdraw them. 
In addition to the planned use and sharing described above, we might remove all identifiers and 
codes from your specimens and data and use or share them with other researchers for future 
research at the NIH or other places.  When we or the other researchers access your anonymized 
            1  010 
                   10/31/2022
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 10/07/[ADDRESS_839794] number; and your data will be labeled with only a code. We cannot offer you a choice of 
whether your data to be placed in this database or not.  If you do not wish to have your data 
placed in this database, you should not enroll in this study.  
How long will your specimens and data be stored by [CONTACT_18121]?
Your specimens and data may be stored by [CONTACT_100437]. 
Risks of storage and sharing of specimens and data
When we store your specimens and data
,
 we take precautions to protect your information from 
others that should not have access to it. When we share your specimens and data, we will do 
everything we can to protect your identity, for example, when appropriate, we remove information 
that can identify you. Even with the safeguards we put in place, we cannot guarantee that your 
identity will never become known or someone may gain unauthorized access to your information. 
New methods may be created in the future that could make it possible to re-identify your specimens 
and data.
PAYMENT
Will you receive any type of payment for taking part in this study?
You will be compensated for your time and inconvenience. Total compensation for completion of 
the study will be between $2500 to $4900 and is based on the number and type of study visits you 
complete. You will get: 

$200 for scheduled visits with a blood draw.

$85 for clinic visits that do not include a blood draw.

$[ADDRESS_839795] administration visit(s) with blood draws on the same day. 

$[ADDRESS_839796] administration visit(s) with blood draws on the same day.  

$[ADDRESS_839797] administration visit(s) with no blood draw.  

$[ADDRESS_839798] deposit into a 
bank account that you specify to the Volunteer Payment Office.  If you are unable to finish the 
study, you will receive compensation
 
for the parts you completed.  Your compensation may need 
to be reported to the internal revenue service (IRS) as taxable income.  IRS “Form 1099-Other 
            1  010 
                   10/31/2022
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 10/07/[ADDRESS_839799]
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
Income” will be sent to you if your total payments for research participation are $600 or more in 
a calendar year. 
We will need your social security number to process your payment. You can still take part in the 
study if you don’t give us your social security number, but you might not be able to get your 
payment. If you have unpaid debt to the federal government, some or all of your compensation 
may be automatically reduced to repay your debt.
REIMBURSEMENT
Will you receive reimbursement or direct payment by [CONTACT_100440]?
This study does not offer reimbursement for, or payment of, travel, lodging or meals.
COSTS
Will taking part in this research study cost you anything?
NIH does not bill health insurance companies or participants for any research or related clinical 
care that you receive at the NIH Clinical Center. 
CONFLICT OF INTEREST (COI) 
The NIH reviews NIH staff researchers at least yearly for conflicts of interest.  This process is 
detailed in a COI Guide.  You may ask your research team for a copy of the COI Guide or for more 
information.  Members of the research team who do not work for NIH are expected to follow these 
guidelines or the guidelines of their home institution, but they do not need to report their personal 
The NIH and the research team for this study have developed N6LS being used in this study. 
This means it is possible that the results of this study could lead to payments to NIH. By [CONTACT_2371], the 
government is required to share such payments with the employee inventors. You will not 
receive any money from the development of N6LS
. 
CLINICAL TRIAL REGISTRATION AND RESULTS REPORTING 
A description of this clinical trial will be available on 
http://www.ClinicalTrials.gov, as required 
by U.S. Law. This Web site will not include information that can identify you. At most, the Web 
site will include a summary of the results. You can search this Web site at any time.
CONFIDENTIALITY PROTECTIONS PROVIDED IN THIS STUDY  
Will your medical information be kept private? 
We will do our best to make sure that the personal information in your medical record will be kept 
private.  However, we cannot guarantee total privacy.  Organizations that may look at and/or copy 
your medical records for research, quality assurance, and data analysis include:

The NIH and other government agencies, like the Food and Drug Administration (FDA), 
which are involved in keepi[INVESTIGATOR_60771].

National Institutes of Health Intramural Institutional Review Board
            1  010 
                   10/31/2022
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 10/07/[ADDRESS_839800]
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY

The study Sponsor, Vaccine Research Center, NIAID or their agent(s) 

Qualified representatives from Halozyme Therapeutics, the pharmaceutical company who 
produces rHuPH20.
The researchers conducting this study and the NIH follow applicable laws and policies to keep 
your identifying information private to the extent possible.  However, there is always a chance 
that, despi[INVESTIGATOR_212095], your identity and/or information about your participation in this 
research may be inadvertently released or improperly accessed by [CONTACT_35532].
In most cases, the NIH will not release any identifiable information collected about you without 
your written permission.  However, your information may be shared as described in the section of 
this document on sharing of specimens and data, and as further outlined in the following sections.  
Further, the information collected for this study is protected by [CONTACT_100441] a Certificate of 
Confidentiality and the Privacy Act. 
Certificate of Confidentiality
To help us protect your privacy, the NIH Intramural Program has received a Certificate of 
Confidentiality (Certificate). With this certificate, researchers may not release or use data or 
information about you except in certain circumstances.  
NIH researchers must not share information that may identify you in any federal, state, or local 
civil, criminal, administrative, legislative, or other proceedings, for example, if requested by a 
court.  
The Certificate does not protect your information when it:  
1. is disclosed to people connected with the research, for example, information may be used 
for auditing or program evaluation internally by [CONTACT_18121]; or 
2. is required to be disclosed by [CONTACT_4496], State, or local laws, for example, when information 
must be disclosed to meet the legal requirements of the federal Food and Drug 
Administration (FDA); 
3. is for other research;
4. is disclosed with your consent. 
The Certificate does not prevent you from voluntarily releasing information about yourself or your 
involvement in this research. 
The Certificate will not be used to prevent disclosure to state or local authorities of harm to self or 
others including, for example, child abuse and neglect, and by [CONTACT_100442]. Other permissions for release may be made by [CONTACT_100443], such as the Notice 
and Acknowledgement of Information Practices consent.
Privacy Act
The Federal Privacy Act generally protects the confidentiality of your NIH medical information 
that we collect under the authority of the Public Health Service Act.  In some cases, the Privacy 
Act protections differ from the Certificate of Confidentiality.  For example, sometimes the Privacy 
Act allows release of information from your record without your permission, for example, if it is 
requested by [CONTACT_100444]. Information may also be released for certain research purposes with due 
            1  010 
                   10/31/2022
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 10/07/[ADDRESS_839801] Wu, 
nother researcher you may call is:
 
 You may also call the NIH Clinical Center Patient Representative at  
or the NIH Office of IRB Operations, at  if you have a research-related complaint 
or concern.
CONSENT DOCUMENT 
Please keep a copy of this document in case you want to read it again.
            1  010 
                   10/31/2022
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 10/07/[ADDRESS_839802]
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
Adult Research Participant: 
I have read the explanation about this study and have been given the opportunity 
to discuss it and to ask questions. I consent to participate in this study.
Signature [CONTACT_289652]:
Signature [CONTACT_100450]:
1. A short form consent process has been used to enroll a non-English speaking subject or
2. An oral presentation of the full consent has been used to enroll a blind or illiterate subject
Signature [CONTACT_100451]:
An interpreter, or other individual, who speaks English and the participant’s preferred language facilitated
the administration of informed consent and served as a witness.
 
The investigator obtaining consent may not 
also serve as the witness.
An interpreter, or other individual, who speaks English and the participant’s preferred language facilitated
the administration of informed consent but did not serve as a witness. The name [CONTACT_289653]:
.
            1  010 
                   10/31/2022
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (2)
Version Date: 10/07/2022, V8.[ADDRESS_839803]
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
PRINCIPAL INVESTIGATOR:  [INVESTIGATOR_100364]; VRC, NIAID
STUDY TITLE:  
VRC 609: A Phase I, Open-Label, Dose-Escalation Study of the Safety and 
Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), 
Administered Intravenously or Subcutaneously with or Without Recombinant Human 
Hyaluronidase PH20 (rHUPH20) to Healthy Adults
STUDY SITE:  
NIH Clinical Center
Cohort: 
Healthy volunteer supplemental
Supplementary Consent Version:  
October 07, 2022, Version 8.[ADDRESS_839804] ABOUT THIS STUDY? 
Principal Investigator: [INVESTIGATOR_100364], M.D.,
Study Coordinator:
Supplementary consent for extended genetic testing (optional)
You agreed to participate in VRC [ADDRESS_839805] your privacy, the NIH Intramural Program has received a Certificate of 
Confidentiality (Certificate). With this certificate, researchers may not release or use data or 
information about you except in certain circumstances.  
            1  010 
                   10/31/2022
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (2)
Version Date: 10/07/2022, V8.[ADDRESS_839806] your information when it:  
1. is disclosed to people connected with the research, for example, information may be used 
for auditing or program evaluation internally by [CONTACT_18121]; or 
2. is required to be disclosed by [CONTACT_4496], State, or local laws, for example, when information 
must be disclosed to meet the legal requirements of the federal Food and Drug 
Administration (FDA); 
3. is for other research;
4. is disclosed with your consent. 
The Certificate does not prevent you from voluntarily releasing information about yourself or your 
involvement in this research. 
The Certificate will not be used to prevent disclosure to state or local authorities of harm to self or 
others including, for example, child abuse and neglect, and by [CONTACT_100442]. Other permissions for release may be made by [CONTACT_100443], such as the Notice 
and Acknowledgement of Information Practices consent.
Privacy Act
The Federal Privacy Act generally protects the confidentiality of your NIH medical information 
that we collect under the authority of the Public Health Service Act.  In some cases, the Privacy 
Act protections differ from the Certificate of Confidentiality.  For example, sometimes the Privacy 
Act allows release of information from your record without your permission, for example, if it is 
requested by [CONTACT_100444]. Information may also be released for certain research purposes with due 
consideration and protection, to those engaged by [CONTACT_100445], to certain 
federal and state agencies, for HIV partner notification, for infectious disease or abuse or neglect 
reporting,  to tumor registries, for quality assessment and medical audits, or when the NIH is 
involved in a lawsuit.  However, NIH will only release information from your medical record if it 
is permitted by [CONTACT_289651].
POLICY REGARDING RESEARCH-RELATED INJURIES  
The NIH Clinical Center will provide short-term medical care for any injury resulting from your 
participation in research here. In general, no long-term medical care or financial compensation for 
research-related injuries will be provided by [CONTACT_18121], the NIH Clinical Center, or the Federal 
Government. However, you have the right to pursue legal remedy if you believe that your injury 
justifies such action.
PROBLEMS OR QUESTIONS
If you have any problems or questions about this study, or about your rights as a research 
participant, or about any research-related injury, contact [CONTACT_079], Richard Wu, 
M.D.  Another researcher you may call is
  You may also call the NIH Clinical Center Patient Representative at 
            1  010 
                   10/31/2022
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (2)
Version Date: 10/07/2022, V8.[ADDRESS_839807] a research-related 
complaint or concern.
CONSENT DOCUMENT 
Please keep a copy of this document in case you want to read it again.
            1  010 
                   10/31/2022
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (2)
Version Date: 10/07/2022, V8.[ADDRESS_839808]
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
Adult Research Participant: 
I have read the explanation about this study and have been given the opportunity 
to discuss it and to ask questions. I consent to participate in this study.
Signature [CONTACT_289652]:
Signature [CONTACT_629634]-form consent process only: 
This section is only required if you are doing the oral 
short-consent process with a non-English speaking subject and this English consent form has been approved 
by [CONTACT_387725].
Witness:
Signature [CONTACT_59931]
*
Print Name [CONTACT_387727]
*NIH ADMINISTRATIVE SECTION TO BE COMPLETED REGARDING THE USE OF AN 
INTERPRETER:
An interpreter, or other individual, who speaks English and the participant’s preferred language facilitated
the administration of informed consent and served as a witness.
 
The investigator obtaining consent may not 
also serve as the witness.
An interpreter, or other individual, who speaks English and the participant’s preferred language facilitated
the administration of informed consent but did not serve as a witness. The name [CONTACT_289653]:
.
            1  010 
                   10/31/2022